Explanation
This regulatory network was inferred from the input dataset. The miRNAs and mRNAs are
presented as round and rectangle nodes respectively. The numerical value popped up upon mouse over the gene node is the log2 transformed fold-change of the gene expression between the two groups. All of the nodes are clickable, and the detailed information of the miRNAs/mRNAs and related cancer pathway will be displayed in another window. The edges between nodes are supported by both interactions (predicted or experimentally verified) and correlations learnt from cancer dataset. The numerical value popped up upon mouse over the edge is the correlation beat value (effect size) between the two nodes. The experimental evidences of the edges reported in previous cancer studies are highlighted by red/orange color. All of these information can be accessed by the "mouse-over" action. This network shows a full map of the miRNA-mRNA regulation of the input gene list(s), and the hub miRNAs (with the high network degree/betweenness centrality) would be the potential cancer drivers or tumor suppressors. The full result table can be accessed in the "Regulations" tab.
"miRNACancerMAP" is also a network visualization tool for users to draw their regulatory network by personal customization. Users can set the complexity of the network by limiting the number of nodes or edges. And the color of the nodes can be defined by different categories of the mRNAs and miRNAs, such as Gene-Ontology, pathway, and expression status. Users can also select to use network degree or network betweenness centrality to define the node size. And edges can be black or colored by the correlation. Purple edge means negative correlation (mostly found between miRNA and mRNA), and blue edge means positive correlation (found in PPI or miRNA-miRNA sponge effect). We can also add the protein-protein interactions (PPI) into the network. This result will show the cluster of genes regulated by some specific miRNAs. Additionally, miRNA-miRNA edges can be added by the "miRNA sponge" button, presenting some clusters of miRNAs that have the interactions via sponge effect.
miRNA-gene regulations
| Num | microRNA | Gene | miRNA log2FC | miRNA pvalue | Gene log2FC | Gene pvalue | Interaction | Correlation beta | Correlation P-value | PMID | Reported in cancer studies |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | hsa-let-7b-5p | AIFM1 | 0.16 | 0.92777 | -0.05 | 0.94518 | miRNATAP | -0.16 | 0.0007 | NA | |
| 2 | hsa-miR-106a-5p | AKT3 | -0.19 | 0.7766 | 0.2 | 0.64987 | miRNATAP | -0.12 | 0.02117 | NA | |
| 3 | hsa-miR-106b-5p | AKT3 | -0.11 | 0.91815 | 0.2 | 0.64987 | miRNATAP | -0.41 | 1.0E-5 | NA | |
| 4 | hsa-miR-142-3p | AKT3 | 0.04 | 0.97824 | 0.2 | 0.64987 | miRanda | -0.16 | 0.00934 | NA | |
| 5 | hsa-miR-15a-5p | AKT3 | -0.01 | 0.99353 | 0.2 | 0.64987 | miRNAWalker2 validate; miRTarBase; miRNATAP | -0.37 | 0.00021 | NA | |
| 6 | hsa-miR-15b-5p | AKT3 | 0.01 | 0.99351 | 0.2 | 0.64987 | miRNATAP | -0.25 | 0.00571 | NA | |
| 7 | hsa-miR-16-5p | AKT3 | 0.01 | 0.99567 | 0.2 | 0.64987 | miRNAWalker2 validate; miRTarBase; miRNATAP | -0.31 | 0.00086 | NA | |
| 8 | hsa-miR-17-5p | AKT3 | -0 | 0.99959 | 0.2 | 0.64987 | TargetScan; miRNATAP | -0.17 | 0.02914 | NA | |
| 9 | hsa-miR-29b-2-5p | AKT3 | 0.05 | 0.91445 | 0.2 | 0.64987 | mirMAP | -0.23 | 0.01747 | NA | |
| 10 | hsa-miR-29b-3p | AKT3 | 0.14 | 0.9001 | 0.2 | 0.64987 | miRNATAP | -0.28 | 0.00031 | 26512921 | MicroRNA 29B mir 29b regulates the Warburg effect in ovarian cancer by targeting AKT2 and AKT3 |
| 11 | hsa-miR-3065-5p | AKT3 | -0.32 | 0.31142 | 0.2 | 0.64987 | mirMAP | -0.22 | 0 | NA | |
| 12 | hsa-miR-362-3p | AKT3 | 0.08 | 0.76325 | 0.2 | 0.64987 | miRanda | -0.25 | 0.00124 | NA | |
| 13 | hsa-miR-501-3p | AKT3 | -0.21 | 0.74913 | 0.2 | 0.64987 | miRNATAP | -0.18 | 0.00733 | NA | |
| 14 | hsa-miR-502-3p | AKT3 | -0.07 | 0.86362 | 0.2 | 0.64987 | miRNATAP | -0.23 | 0.03065 | NA | |
| 15 | hsa-miR-93-5p | AKT3 | -0.1 | 0.94883 | 0.2 | 0.64987 | miRNATAP | -0.33 | 0.00021 | NA | |
| 16 | hsa-miR-155-5p | APAF1 | 0.15 | 0.89462 | 0.05 | 0.93643 | miRNAWalker2 validate | -0.11 | 0.0002 | 22996741; 26877850 | MiR 155 inhibits the sensitivity of lung cancer cells to cisplatin via negative regulation of Apaf 1 expression; The objective of this study is to verify the hypothesis based on the results of bioinformatics analysis that miR-155 modulates cellular apoptosis and DNA damage through the regulation of Apaf-1 and is thus involved in the development and progression of lung cancer; First we measured the expression of miR-155 and the Apaf-1 protein in lung cancer tissues; The results showed that expression of miR-155 was significantly higher in lung cancer tissues than in paracancerous and normal tissues; whereas Apaf-1 expression was lower in the lung cancerous tissues; The results showed that relative to controls the silencing of miR-155 resulted in elevated expression of the Apaf-1 protein whereas Apaf-1 mRNA levels remained unchanged; Both the silencing of miR-155 and the overexpression Apaf-1 greatly increased the sensitivity of A549 cells to cisplatin treatment as evidenced by elevated rates of apoptosis and DNA damage; Furthermore dual-transfection of A549 cells with miR-155 siRNA and Apaf-1 siRNA resulted in the attenuation of apoptosis and DNA damage;Also increase in the transcript level of APAF-1 and CASP-9 after downregulation of miR-21 and miR-155 might indicate that these genes were targeted by aforementioned miRNAs in T47D cells |
| 17 | hsa-miR-23a-3p | APAF1 | -0 | 0.99951 | 0.05 | 0.93643 | miRNATAP | -0.25 | 1.0E-5 | 24992592; 24249161 | Luciferase assay was performed to verify a putative target site of miR-23a in the 3'-UTR of apoptosis protease activating factor 1 APAF1 mRNA; The expression levels of miR-23a and APAF1 in CRC cell lines SW480 and SW620 and clinical samples were assessed using reverse transcription-quantitative real-time PCR RT-qPCR and Western blot; Moreover miR-23a up-regulation was coupled with APAF1 down-regulation in CRC tissue samples;We found that the expression of miR-23a was increased and the level of apoptosis-activating factor-1 APAF-1 was decreased in 5-FU-treated colon cancer cells compared to untreated cells; APAF-1 as a target gene of miR-23a was identified and miR-23a antisense-induced increase in the activation of caspase-9 was observed |
| 18 | hsa-miR-23b-3p | APAF1 | -0.04 | 0.97439 | 0.05 | 0.93643 | miRNATAP | -0.16 | 0.00048 | NA | |
| 19 | hsa-miR-27a-3p | APAF1 | 0.09 | 0.95011 | 0.05 | 0.93643 | miRNATAP | -0.18 | 3.0E-5 | NA | |
| 20 | hsa-miR-27b-3p | APAF1 | -0.04 | 0.97527 | 0.05 | 0.93643 | miRNATAP | -0.16 | 6.0E-5 | NA | |
| 21 | hsa-miR-374b-5p | APAF1 | -0.12 | 0.87256 | 0.05 | 0.93643 | mirMAP | -0.13 | 0.01531 | NA | |
| 22 | hsa-miR-590-3p | APAF1 | -0.14 | 0.70045 | 0.05 | 0.93643 | PITA; miRanda; mirMAP; miRNATAP | -0.12 | 0.0034 | NA | |
| 23 | hsa-miR-590-5p | APAF1 | -0.17 | 0.73474 | 0.05 | 0.93643 | miRanda | -0.1 | 0.01383 | NA | |
| 24 | hsa-miR-664a-3p | APAF1 | 0.04 | 0.94126 | 0.05 | 0.93643 | mirMAP | -0.11 | 0.01914 | NA | |
| 25 | hsa-miR-708-3p | APAF1 | -0.03 | 0.97114 | 0.05 | 0.93643 | mirMAP | -0.12 | 2.0E-5 | NA | |
| 26 | hsa-miR-203a-3p | ATM | -0.15 | 0.93662 | -0.05 | 0.93782 | MirTarget | -0.11 | 0 | 24145123; 27542403 | miR 203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase; In silico analysis identified ataxia telangiectasia mutated ATM a primary mediator of the DNA damage response as a potential target of miR-203; Using TCGA database we identified a significant reverse correlation of miR-203 and ATM expression in CRC tissues; We validated ATM as a bona fide target of miR-203 in CRC cells; Mutation of the putative miR-203 binding site in the 3' untranslated region 3'UTR of the ATM mRNA abolished the inhibitory effect of miR-203 on ATM;MiR 203 inhibits tumor invasion and metastasis in gastric cancer by ATM; Our results showed that miR-203 was significantly downregulated in gastric cancer tissues and cells while ataxia telangiectasia mutated kinase ATM was upregulated in gastric cancer tissues and cells and was directly regulated by miR-203; ATM knockdown phenocopied the effect of miR-203 overexpression |
| 27 | hsa-miR-27a-5p | ATM | 0.05 | 0.94069 | -0.05 | 0.93782 | MirTarget | -0.12 | 0.00046 | NA | |
| 28 | hsa-miR-30e-3p | ATM | 0.04 | 0.97717 | -0.05 | 0.93782 | mirMAP | -0.16 | 0.0051 | NA | |
| 29 | hsa-miR-339-5p | ATM | -0.04 | 0.94751 | -0.05 | 0.93782 | miRanda | -0.16 | 0.00017 | NA | |
| 30 | hsa-miR-590-3p | ATM | -0.14 | 0.70045 | -0.05 | 0.93782 | miRanda; mirMAP | -0.12 | 0.01272 | NA | |
| 31 | hsa-miR-590-5p | ATM | -0.17 | 0.73474 | -0.05 | 0.93782 | mirMAP | -0.13 | 0.00485 | NA | |
| 32 | hsa-miR-92a-3p | ATM | 0.03 | 0.98479 | -0.05 | 0.93782 | miRNAWalker2 validate | -0.14 | 0.01126 | NA | |
| 33 | hsa-miR-15b-3p | BCL2 | -0.11 | 0.88561 | -0.09 | 0.85335 | mirMAP | -0.16 | 0.0243 | 25594541; 26915294; 26884837; 18449891 | MicroRNAs miRNAs encoded by the miR-15 cluster are known to induce G1 arrest and apoptosis by targeting G1 checkpoints and the anti-apoptotic B cell lymphoma 2 BCL-2 gene;As a result transcript levels of the tumor-suppressive miR-15 and let-7 families increased which targeted and decreased the expression of the crucial prosurvival genes BCL-2 and BCL-XL respectively;MiR 15b mediates liver cancer cells proliferation through targeting BCL 2; MiR-15b overexpression downregulated BCL2 mRNA and protein expression obviously P < 0.05; On the contrary miR-15b inhibitor transfection markedly reduced miR-15b expression in liver cancer cells P < 0.05 promoted tumor cell proliferation and increased BCL2 mRNA and protein expression; MiR-15b can inhibit HepG2 cell proliferation and down-regulate BCL2 mRNA and protein expression;miR 15b and miR 16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells; The downregulation of miR-15b and miR-16 in SGC7901/VCR cells was concurrent with the upregulation of Bcl-2 protein; Taken together our findings suggest that miR-15b and miR-16 could play a role in the development of MDR in gastric cancer cells at least in part by modulation of apoptosis via targeting BCL2 |
| 34 | hsa-miR-15b-5p | BCL2 | 0.01 | 0.99351 | -0.09 | 0.85335 | miRNAWalker2 validate; miRTarBase | -0.18 | 0.02793 | 25594541; 26915294; 26884837; 18449891 | MicroRNAs miRNAs encoded by the miR-15 cluster are known to induce G1 arrest and apoptosis by targeting G1 checkpoints and the anti-apoptotic B cell lymphoma 2 BCL-2 gene;As a result transcript levels of the tumor-suppressive miR-15 and let-7 families increased which targeted and decreased the expression of the crucial prosurvival genes BCL-2 and BCL-XL respectively;MiR 15b mediates liver cancer cells proliferation through targeting BCL 2; MiR-15b overexpression downregulated BCL2 mRNA and protein expression obviously P < 0.05; On the contrary miR-15b inhibitor transfection markedly reduced miR-15b expression in liver cancer cells P < 0.05 promoted tumor cell proliferation and increased BCL2 mRNA and protein expression; MiR-15b can inhibit HepG2 cell proliferation and down-regulate BCL2 mRNA and protein expression;miR 15b and miR 16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells; The downregulation of miR-15b and miR-16 in SGC7901/VCR cells was concurrent with the upregulation of Bcl-2 protein; Taken together our findings suggest that miR-15b and miR-16 could play a role in the development of MDR in gastric cancer cells at least in part by modulation of apoptosis via targeting BCL2 |
| 35 | hsa-miR-16-2-3p | BCL2 | -0.07 | 0.90793 | -0.09 | 0.85335 | mirMAP | -0.2 | 0.00813 | NA | |
| 36 | hsa-miR-16-5p | BCL2 | 0.01 | 0.99567 | -0.09 | 0.85335 | miRNAWalker2 validate; miRTarBase | -0.27 | 0.00125 | 21336967; 24447552; 18449891; 25435430; 24598659; 18931683; 22966344; 25623762 | P glycoprotein enhances radiation induced apoptotic cell death through the regulation of miR 16 and Bcl 2 expressions in hepatocellular carcinoma cells; RHepG2 cells the multidrug resistant subline of human hepatocellular carcinoma HepG2 cells expressed higher levels of Pgp as well as miR-16 and lower level of Bcl-2 than the parental cells; On the other hand ectopic mdr1 expression enhanced radiation-induced apoptosis in HepG2 cells SK-HEP-1 cells MiHa cells and furthermore induced miR-16 and suppressed its target gene Bcl-2 in HepG2 cells; Moreover the enhancement effects of Pgp and miR-16 on radiation-induced apoptosis were counteracted by overexpression of Bcl-2;To study the expression of miR-16 and bcl-2 in T lymphoblastic lymphoma/leukemia T-LBL/ALL and its relationship to prognosis; The relationship of miR-16 and bcl-2 was significantP = 0.042χ2 = 4.147; The relationship of miR-16 and bcl-2 might suggested that gene regulation may be influenced by them;miR 15b and miR 16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells; The downregulation of miR-15b and miR-16 in SGC7901/VCR cells was concurrent with the upregulation of Bcl-2 protein; Taken together our findings suggest that miR-15b and miR-16 could play a role in the development of MDR in gastric cancer cells at least in part by modulation of apoptosis via targeting BCL2;We demonstrated that anti-apoptotic protein Bcl-2 was directly targeted miR-16 in paclitaxel resistant lung cancer cells; Combined overexpression of miR-16 and miR-17 greatly reduced Beclin-1 and Bcl-2 expressions respectively; miR-17 overexpression reduced cytoprotective autophagy by targeting Beclin-1 whereas overexpression of miR-16 potentiated paclitaxel induced apoptotic cell death by inhibiting anti-apoptotic protein Bcl-2;The miR-16 expression correlated with BCL-2 protein r = 0.51 P < 0.05;MicroRNAs miRNAs are noncoding small RNAs that repress protein translation by targeting specific messenger RNAs miR-15a and miR-16-1 act as putative tumor suppressors by targeting the oncogene BCL2;The overall objective of our investigation was to assess whether miRNA-16 miR-16 is involved in the regulation of critical genes such as BCL2 that control the sensitivity of pancreatic cancer cells to apoptosis; This study showed that the ectopic overexpression of miR-16 may be therapeutically beneficial as is evidenced by impaired cell survival with concomitant attenuation of anti-apoptotic protein Bcl-2; Moreover the luciferase reporter assay suggested that miR-16 post-transcriptionally regulates Bcl-2 expression in pancreatic cancer cells through the target sites of the 3' untranslated region of this gene;miR 15a and miR 16 modulate drug resistance by targeting bcl 2 in human colon cancer cells; To investigate the reversal effect of targeted modulation of bcl-2 expression by miR-15a and miR-16 on drug resistance of human colon cancer cells |
| 37 | hsa-miR-192-5p | BCL2 | 0.21 | 0.8622 | -0.09 | 0.85335 | miRNAWalker2 validate | -0.13 | 0.00025 | 26550150 | MicroRNA 192 regulates chemo resistance of lung adenocarcinoma for gemcitabine and cisplatin combined therapy by targeting Bcl 2; In this paper we try to test whether miR-192 regulates chemo-resistance in human carcinoma A549 mice model by targeting Bcl-2; MTT assay real-time RT-PCR western blotting assay were used to investigate miR-192 expression levels cell viability ratio and Bcl-2 protein expression levels; Bcl-2 mRNA and protein expression levels up-regulated in miR-192 inhibitor treated tumor; Bcl-2 is a key regulator for miR-192 related chemotherapy resistance; In this study we demonstrate that miR-192 regulates chemoresistance for gemcitabine and cisplatin combined chemotherapy in human adenocarcinoma lung cancer A549 cells and Bcl-2 is the target of miR-192 |
| 38 | hsa-miR-200a-5p | BCL2 | 0.06 | 0.96445 | -0.09 | 0.85335 | mirMAP | -0.2 | 0.00037 | NA | |
| 39 | hsa-miR-200b-3p | BCL2 | 0.01 | 0.99556 | -0.09 | 0.85335 | miRNAWalker2 validate; miRTarBase; TargetScan; mirMAP | -0.11 | 0.03933 | NA | |
| 40 | hsa-miR-200b-5p | BCL2 | 0.05 | 0.93779 | -0.09 | 0.85335 | mirMAP | -0.2 | 0.00019 | NA | |
| 41 | hsa-miR-200c-3p | BCL2 | 0.1 | 0.95219 | -0.09 | 0.85335 | miRNAWalker2 validate; miRTarBase; mirMAP | -0.2 | 0.00073 | NA | |
| 42 | hsa-miR-20a-3p | BCL2 | 0.01 | 0.98963 | -0.09 | 0.85335 | mirMAP | -0.16 | 0.0222 | NA | |
| 43 | hsa-miR-21-5p | BCL2 | 0.1 | 0.9651 | -0.09 | 0.85335 | miRNAWalker2 validate; miRTarBase | -0.48 | 4.0E-5 | 21468550; 25994220; 25381586; 26555418; 23359184; 22964582; 21376256 | BCL-2 up-regulation could be achieved by miR-21 overexpression which prevented T24 cells from apoptosis induced by doxorubicin; Furthermore the miR-21 induced BCL-2 up-regulation could be cancelled by the PI3K inhibitor LY294002;Meanwhile miR-21 loss reduced STAT3 and Bcl-2 activation causing an increase in the apoptosis of tumour cells in CAC mice;Changes in the sensitivity of osteosarcoma cells to CDDP were examined after transfection with miR-21 mimics or anti-miR-21 or bcl-2 siRNA in combination with CDDP;The expression of Bax Bcl-2 and miR-21 in parental and paclitaxel-resistant cells was detected by RT-PCR and Western blotting;Resveratrol induces apoptosis of pancreatic cancers cells by inhibiting miR 21 regulation of BCL 2 expression; We also used Western blot to measure BCL-2 protein levels after down-regulation of miR-21 expression; Besides down-regulation of miR-21 expression can inhibit BCL-2 expression in PANC-1 CFPAC-1 and MIA Paca-2 cells; Over-expression of miR-21 expression can reverse down-regulation of BCL-2 expression and apoptosis induced by resveratrol; In this study we demonstrated that the effect of resveratrol on apoptosis is due to inhibiting miR-21 regulation of BCL-2 expression;Tumors harvested from these lungs have elevated levels of oncogenic miRNAs miR-21 and miR-155; are deficient for p53-regulated miRNAs; and have heightened expression of miR-34 target genes such as Met and Bcl-2;Bcl 2 upregulation induced by miR 21 via a direct interaction is associated with apoptosis and chemoresistance in MIA PaCa 2 pancreatic cancer cells; However the roles and mechanisms of miRNA miR-21 in regulation of Bcl-2 in pancreatic cancer remain to be elucidated; Then luciferase activity was observed after miR-21 mimics and pRL-TK plasmids containing wild-type and mutant 3'UTRs of Bcl-2 mRNA were co-transfected; Cells transfected with miR-21 inhibitor revealed an opposite trend. There was a significant increase in luciferase activity in the cells transfected with the wild-type pRL-TK plasmid in contrast to those transfected with the mutant one indicating that miR-21 promotes Bcl-2 expression by binding directly to the 3'UTR of Bcl-2 mRNA; Upregulation of Bcl-2 directly induced by miR-21 is associated with apoptosis chemoresistance and proliferation of MIA PaCa-2 pancreatic cancer cells |
| 44 | hsa-miR-215-5p | BCL2 | -0.08 | 0.8686 | -0.09 | 0.85335 | miRNAWalker2 validate | -0.14 | 1.0E-5 | NA | |
| 45 | hsa-miR-24-2-5p | BCL2 | -0.01 | 0.98834 | -0.09 | 0.85335 | miRNAWalker2 validate; miRTarBase | -0.36 | 0 | NA | |
| 46 | hsa-miR-3065-5p | BCL2 | -0.32 | 0.31142 | -0.09 | 0.85335 | mirMAP | -0.17 | 0.00011 | NA | |
| 47 | hsa-miR-32-3p | BCL2 | 0.4 | 0.03721 | -0.09 | 0.85335 | mirMAP | -0.16 | 0.01564 | NA | |
| 48 | hsa-miR-338-5p | BCL2 | -0.06 | 0.85281 | -0.09 | 0.85335 | PITA | -0.15 | 0.00173 | NA | |
| 49 | hsa-miR-33b-5p | BCL2 | -0.12 | 0.752 | -0.09 | 0.85335 | miRTarBase; mirMAP | -0.12 | 0.00899 | NA | |
| 50 | hsa-miR-365a-3p | BCL2 | -0.02 | 0.9772 | -0.09 | 0.85335 | miRNAWalker2 validate; miRTarBase | -0.39 | 0 | NA | |
| 51 | hsa-miR-429 | BCL2 | -0.2 | 0.8303 | -0.09 | 0.85335 | miRNAWalker2 validate; miRTarBase; PITA; mirMAP | -0.16 | 0.00181 | 23999873; 26513239; 26511969 | MiR 429 up regulation induces apoptosis and suppresses invasion by targeting Bcl 2 and SP 1 in esophageal carcinoma; Subsequent Western blotting and luciferase reporter assays showed that miR-429 can bind to putative binding sites within the Bcl-2 and SP1 mRNA 3' untranslated regions UTRs to reduce their expression; Up-regulation of miR-429 inhibits invasion and promotes apoptosis in EC cells by targeting Bcl-2 and SP1; Our findings suggest that Bcl-2 and SP1 may serve as major targets of miR-429;MiR 429 Induces Gastric Carcinoma Cell Apoptosis Through Bcl 2; Here we studied the levels of miR-429 and anti-apoptotic protein Bcl-2 in GC specimens; We performed bioinformatics analyses and used luciferase-reporter assay to analyze the relationship between miR-429 and Bcl-2 in GC cells; MiR-429 levels were significantly decreased and Bcl-2 levels were significantly increased in GC specimens compared to the paired adjacent non-tumor gastric tissue; Moreover the levels of miR-429 and Bcl-2 inversely correlated in GC specimens; Bioinformatics analyses showed that miR-429 targeted the 3'-UTR of Bcl-2 mRNA to inhibit its translation which was confirmed by luciferase-reporter assay;MiR 429 induces apoptosis of glioblastoma cell through Bcl 2; Here we analyzed the levels of miR-429 and anti-apoptotic protein Bcl-2 in GBM specimens; We combined bioinformatics analyses and luciferase reporter assay to determine the relationship between miR-429 and Bcl-2 in GBM cells; We found that miR-429 levels were significantly decreased and Bcl-2 levels were significantly increased in GBM specimens compared to the paired adjacent non-tumor brain tissue; Moreover the levels of miR-429 and Bcl-2 inversely correlated; MiR-429 targeted the 3'-UTR of Bcl-2 mRNA to inhibit its translation |
| 52 | hsa-miR-582-5p | BCL2 | 0.04 | 0.94537 | -0.09 | 0.85335 | PITA | -0.13 | 0.00231 | NA | |
| 53 | hsa-miR-590-5p | BCL2 | -0.17 | 0.73474 | -0.09 | 0.85335 | miRanda | -0.17 | 0.03245 | NA | |
| 54 | hsa-miR-629-5p | BCL2 | 0.32 | 0.7228 | -0.09 | 0.85335 | mirMAP | -0.25 | 7.0E-5 | NA | |
| 55 | hsa-miR-7-5p | BCL2 | -0.04 | 0.89079 | -0.09 | 0.85335 | miRNAWalker2 validate; miRTarBase; mirMAP | -0.12 | 0.00725 | 26464649; 25862909; 21750649 | Western blotting was used to evaluate the effect of miR-7 on Bcl2 in A549 and H460 cells; Moreover subsequent experiments showed that BCL-2 was downregulated by miR-7 at both transcriptional and translational levels; This study further extends the biological role of miR-7 in NSCLC A549 and H460 cells and identifies BCL-2 as a novel target possibly involved in miR-7-mediated growth suppression and apoptosis induction of NSCLC cells;miR-7 overexpression correlated with diminished BCL2 expression but there was no relationship between miR-7 and EGFR expression neither in tumour samples nor in the cell lines; Of the two postulated miR-7 target genes we examined BCL2 but not EGFR seems to be a possible miR-7 target in OC;Bioinformatics predictions revealed a potential binding site of miR-7 on 3'UTR of BCL-2 and it was further confirmed by luciferase assay; Moreover subsequent experiments showed that BCL-2 was downregulated by miR-7 at both transcriptional and translational levels; These results suggest that miR-7 regulates the expression of BCL-2 through direct 3'UTR interactions |
| 56 | hsa-let-7a-5p | BCL2L1 | -0 | 0.99953 | 0.07 | 0.93446 | TargetScan; miRNATAP | -0.2 | 0.01274 | 26915294; 20347499 | As a result transcript levels of the tumor-suppressive miR-15 and let-7 families increased which targeted and decreased the expression of the crucial prosurvival genes BCL-2 and BCL-XL respectively;The let 7 family of microRNAs inhibits Bcl xL expression and potentiates sorafenib induced apoptosis in human hepatocellular carcinoma; The effect of let-7 on Bcl-xL expression was examined by Western blot and a reporter assay; Microarray analysis followed by in silico target prediction identified let-7 microRNAs as being downregulated in Huh7 hepatoma cells in comparison with primary human hepatocytes as well as possessing a putative target site in the bcl-xl mRNA |
| 57 | hsa-miR-23b-3p | BCL2L1 | -0.04 | 0.97439 | 0.07 | 0.93446 | miRNAWalker2 validate | -0.11 | 0.04171 | NA | |
| 58 | hsa-miR-342-3p | BCL2L1 | 0.15 | 0.86763 | 0.07 | 0.93446 | PITA; miRanda; miRNATAP | -0.13 | 0.00344 | NA | |
| 59 | hsa-miR-342-5p | BCL2L1 | 0.22 | 0.55919 | 0.07 | 0.93446 | miRNATAP | -0.1 | 0.01901 | NA | |
| 60 | hsa-miR-195-3p | BIRC3 | -0.08 | 0.73767 | 1.08 | 0.12934 | mirMAP | -0.22 | 0.01884 | NA | |
| 61 | hsa-miR-20b-3p | BIRC3 | -0.24 | 0.54287 | 1.08 | 0.12934 | MirTarget | -0.13 | 0.02697 | NA | |
| 62 | hsa-miR-24-1-5p | BIRC3 | 0.03 | 0.94846 | 1.08 | 0.12934 | MirTarget | -0.36 | 0.00121 | NA | |
| 63 | hsa-miR-369-3p | BIRC3 | -0.21 | 0.56818 | 1.08 | 0.12934 | MirTarget; miRNATAP | -0.15 | 0.04648 | NA | |
| 64 | hsa-miR-664a-3p | BIRC3 | 0.04 | 0.94126 | 1.08 | 0.12934 | mirMAP | -0.28 | 0.04632 | NA | |
| 65 | hsa-miR-491-5p | CAPN1 | 0.17 | 0.33673 | 0.07 | 0.94569 | miRanda | -0.15 | 5.0E-5 | NA | |
| 66 | hsa-miR-107 | CAPN2 | -0.14 | 0.85595 | 0 | 0.99771 | miRanda | -0.13 | 0.04866 | NA | |
| 67 | hsa-miR-1468-5p | CAPN2 | 0.08 | 0.78679 | 0 | 0.99771 | MirTarget | -0.2 | 0 | NA | |
| 68 | hsa-miR-20a-3p | CAPN2 | 0.01 | 0.98963 | 0 | 0.99771 | MirTarget | -0.14 | 0.00093 | NA | |
| 69 | hsa-miR-421 | CAPN2 | -0.1 | 0.66357 | 0 | 0.99771 | miRanda | -0.11 | 0.00888 | NA | |
| 70 | hsa-miR-125b-5p | CASP10 | 0.23 | 0.84773 | 0.32 | 0.60563 | mirMAP | -0.15 | 0.00696 | NA | |
| 71 | hsa-miR-145-3p | CASP10 | 0.08 | 0.89989 | 0.32 | 0.60563 | mirMAP | -0.15 | 0.02154 | NA | |
| 72 | hsa-miR-145-5p | CASP10 | 0.12 | 0.92884 | 0.32 | 0.60563 | mirMAP | -0.14 | 0.01213 | NA | |
| 73 | hsa-miR-186-5p | CASP10 | -0.03 | 0.97568 | 0.32 | 0.60563 | MirTarget; mirMAP | -0.26 | 0.04094 | NA | |
| 74 | hsa-miR-19b-3p | CASP10 | -0.02 | 0.9825 | 0.32 | 0.60563 | MirTarget; mirMAP | -0.2 | 0.01385 | NA | |
| 75 | hsa-miR-33a-3p | CASP10 | 0.03 | 0.88794 | 0.32 | 0.60563 | mirMAP | -0.16 | 0.01181 | NA | |
| 76 | hsa-miR-361-5p | CASP10 | -0.19 | 0.85441 | 0.32 | 0.60563 | miRanda | -0.46 | 0.00011 | NA | |
| 77 | hsa-miR-429 | CASP10 | -0.2 | 0.8303 | 0.32 | 0.60563 | mirMAP; miRNATAP | -0.13 | 0.01667 | NA | |
| 78 | hsa-miR-501-5p | CASP10 | -0.03 | 0.91483 | 0.32 | 0.60563 | mirMAP | -0.16 | 0.01989 | NA | |
| 79 | hsa-miR-532-5p | CASP10 | -0.11 | 0.92893 | 0.32 | 0.60563 | mirMAP | -0.47 | 0 | NA | |
| 80 | hsa-miR-589-3p | CASP10 | 0.08 | 0.72556 | 0.32 | 0.60563 | mirMAP | -0.23 | 0.00013 | NA | |
| 81 | hsa-miR-592 | CASP10 | 0.05 | 0.90339 | 0.32 | 0.60563 | miRNATAP | -0.1 | 0.0073 | NA | |
| 82 | hsa-miR-744-3p | CASP10 | -0.13 | 0.76829 | 0.32 | 0.60563 | mirMAP | -0.39 | 0 | NA | |
| 83 | hsa-miR-23a-3p | CASP7 | -0 | 0.99951 | 0.04 | 0.95498 | MirTarget | -0.16 | 0.02185 | NA | |
| 84 | hsa-miR-361-5p | CASP7 | -0.19 | 0.85441 | 0.04 | 0.95498 | PITA; miRanda | -0.2 | 0.00762 | NA | |
| 85 | hsa-miR-664a-3p | CASP7 | 0.04 | 0.94126 | 0.04 | 0.95498 | MirTarget | -0.14 | 0.02009 | NA | |
| 86 | hsa-miR-125a-5p | CFLAR | 0.28 | 0.80489 | 0.08 | 0.91358 | miRanda | -0.13 | 0.0064 | NA | |
| 87 | hsa-miR-130b-3p | CFLAR | -0.1 | 0.8629 | 0.08 | 0.91358 | mirMAP | -0.14 | 0.00031 | NA | |
| 88 | hsa-miR-15b-5p | CFLAR | 0.01 | 0.99351 | 0.08 | 0.91358 | mirMAP | -0.1 | 0.03067 | NA | |
| 89 | hsa-miR-301a-3p | CFLAR | -0.1 | 0.82283 | 0.08 | 0.91358 | mirMAP | -0.14 | 0.00017 | NA | |
| 90 | hsa-miR-30b-3p | CFLAR | 0.19 | 0.3422 | 0.08 | 0.91358 | mirMAP | -0.16 | 7.0E-5 | NA | |
| 91 | hsa-miR-582-5p | CHP2 | 0.04 | 0.94537 | -0.05 | 0.94187 | miRNATAP | -0.42 | 0.00313 | NA | |
| 92 | hsa-miR-15b-3p | CSF2RB | -0.11 | 0.88561 | 0.05 | 0.90421 | mirMAP | -0.24 | 0.00379 | NA | |
| 93 | hsa-miR-19b-3p | CSF2RB | -0.02 | 0.9825 | 0.05 | 0.90421 | MirTarget | -0.25 | 0.00793 | NA | |
| 94 | hsa-miR-30b-3p | CSF2RB | 0.19 | 0.3422 | 0.05 | 0.90421 | MirTarget | -0.28 | 0.00087 | NA | |
| 95 | hsa-miR-532-5p | CSF2RB | -0.11 | 0.92893 | 0.05 | 0.90421 | MirTarget | -0.22 | 0.0443 | NA | |
| 96 | hsa-miR-365a-3p | DFFB | -0.02 | 0.9772 | -0.17 | 0.62811 | MirTarget | -0.1 | 0.00471 | NA | |
| 97 | hsa-miR-130b-3p | ENDOD1 | -0.1 | 0.8629 | -0.16 | 0.82147 | MirTarget | -0.12 | 0.00768 | NA | |
| 98 | hsa-miR-16-1-3p | ENDOD1 | -0.02 | 0.9564 | -0.16 | 0.82147 | mirMAP | -0.14 | 0.01455 | NA | |
| 99 | hsa-miR-181a-5p | ENDOD1 | 0.13 | 0.91726 | -0.16 | 0.82147 | MirTarget | -0.19 | 0.00156 | NA | |
| 100 | hsa-miR-181b-5p | ENDOD1 | 0.28 | 0.78042 | -0.16 | 0.82147 | MirTarget | -0.12 | 0.02423 | NA | |
| 101 | hsa-miR-181c-5p | ENDOD1 | 0.35 | 0.60937 | -0.16 | 0.82147 | MirTarget | -0.19 | 0.00075 | NA | |
| 102 | hsa-miR-19a-3p | ENDOD1 | -0.02 | 0.98187 | -0.16 | 0.82147 | mirMAP | -0.12 | 0.00261 | NA | |
| 103 | hsa-miR-19b-3p | ENDOD1 | -0.02 | 0.9825 | -0.16 | 0.82147 | mirMAP | -0.16 | 0.0036 | NA | |
| 104 | hsa-miR-200b-3p | ENDOD1 | 0.01 | 0.99556 | -0.16 | 0.82147 | TargetScan | -0.13 | 0.00092 | NA | |
| 105 | hsa-miR-26b-3p | ENDOD1 | -0.05 | 0.93418 | -0.16 | 0.82147 | mirMAP | -0.15 | 0.00987 | NA | |
| 106 | hsa-miR-301a-3p | ENDOD1 | -0.1 | 0.82283 | -0.16 | 0.82147 | MirTarget | -0.13 | 0.00488 | NA | |
| 107 | hsa-miR-3607-3p | ENDOD1 | -0.06 | 0.92112 | -0.16 | 0.82147 | MirTarget; miRNATAP | -0.11 | 0.01385 | NA | |
| 108 | hsa-miR-3613-5p | ENDOD1 | -0.2 | 0.70593 | -0.16 | 0.82147 | MirTarget | -0.2 | 4.0E-5 | NA | |
| 109 | hsa-miR-362-3p | ENDOD1 | 0.08 | 0.76325 | -0.16 | 0.82147 | miRanda | -0.18 | 0.00023 | NA | |
| 110 | hsa-miR-454-3p | ENDOD1 | 0.14 | 0.74549 | -0.16 | 0.82147 | MirTarget | -0.23 | 4.0E-5 | NA | |
| 111 | hsa-miR-589-3p | ENDOD1 | 0.08 | 0.72556 | -0.16 | 0.82147 | mirMAP | -0.1 | 0.0115 | NA | |
| 112 | hsa-miR-589-5p | ENDOD1 | 0.02 | 0.97555 | -0.16 | 0.82147 | MirTarget | -0.18 | 0.0056 | NA | |
| 113 | hsa-miR-590-3p | ENDOD1 | -0.14 | 0.70045 | -0.16 | 0.82147 | miRanda | -0.22 | 7.0E-5 | NA | |
| 114 | hsa-miR-24-3p | EXOG | -0 | 0.99748 | 0.13 | 0.73958 | MirTarget | -0.14 | 0.00075 | NA | |
| 115 | hsa-miR-106a-5p | FAS | -0.19 | 0.7766 | 0.28 | 0.63811 | miRNAWalker2 validate; miRTarBase | -0.14 | 0.00128 | 22431000; 27142596 | miR 106a is frequently upregulated in gastric cancer and inhibits the extrinsic apoptotic pathway by targeting FAS; Bioinformatic analysis combining with validation experiments identified FAS as a direct target of miR-106a; Moreover a significant inverse correlation was found between miR-106a and FAS expression not only in gastric cancer cell lines but also in gastric cancer specimens; Taken together these findings suggest that ectopicly overexpressed miR-106a may play an oncogenic role in gastric carcinogenesis and impair extrinsic apoptotic pathway through targeting FAS;Functional experiment ascertained that miR-106a interacted with FAS and mediated caspase3 pathway |
| 116 | hsa-miR-361-5p | FAS | -0.19 | 0.85441 | 0.28 | 0.63811 | miRanda | -0.33 | 0.00172 | NA | |
| 117 | hsa-miR-590-5p | FAS | -0.17 | 0.73474 | 0.28 | 0.63811 | miRanda | -0.2 | 0.00636 | NA | |
| 118 | hsa-let-7e-5p | FASLG | 0.2 | 0.87709 | 0.32 | 0.34016 | miRNATAP | -0.31 | 0.02416 | NA | |
| 119 | hsa-miR-199a-5p | FASLG | -0.19 | 0.87328 | 0.32 | 0.34016 | miRanda | -0.4 | 1.0E-5 | NA | |
| 120 | hsa-miR-28-5p | FASLG | 0.11 | 0.89598 | 0.32 | 0.34016 | miRanda | -0.58 | 0.00171 | NA | |
| 121 | hsa-miR-324-5p | FASLG | -0 | 0.99456 | 0.32 | 0.34016 | miRanda | -0.33 | 0.00773 | NA | |
| 122 | hsa-miR-92a-3p | FASLG | 0.03 | 0.98479 | 0.32 | 0.34016 | miRNATAP | -0.37 | 0.01313 | NA | |
| 123 | hsa-miR-92b-3p | FASLG | 0.04 | 0.96614 | 0.32 | 0.34016 | miRNATAP | -0.25 | 0.00986 | NA | |
| 124 | hsa-miR-151a-3p | IKBKB | -0.01 | 0.99333 | 0.07 | 0.92309 | miRNAWalker2 validate | -0.12 | 0.00181 | NA | |
| 125 | hsa-miR-339-5p | IKBKB | -0.04 | 0.94751 | 0.07 | 0.92309 | miRanda | -0.11 | 7.0E-5 | NA | |
| 126 | hsa-miR-542-3p | IKBKB | 0.02 | 0.98096 | 0.07 | 0.92309 | miRanda | -0.11 | 0.00095 | NA | |
| 127 | hsa-miR-107 | IKBKG | -0.14 | 0.85595 | 0.13 | 0.84238 | miRanda | -0.11 | 0.03182 | NA | |
| 128 | hsa-miR-125a-5p | IKBKG | 0.28 | 0.80489 | 0.13 | 0.84238 | miRanda | -0.11 | 0.00712 | NA | |
| 129 | hsa-miR-338-5p | IKBKG | -0.06 | 0.85281 | 0.13 | 0.84238 | mirMAP | -0.11 | 1.0E-5 | NA | |
| 130 | hsa-miR-181c-5p | IL1A | 0.35 | 0.60937 | -0.44 | 0.3987 | MirTarget | -0.75 | 0.00013 | NA | |
| 131 | hsa-miR-181d-5p | IL1A | 0.5 | 0.33057 | -0.44 | 0.3987 | MirTarget | -0.37 | 0.03863 | NA | |
| 132 | hsa-miR-191-5p | IL1A | 0.12 | 0.91687 | -0.44 | 0.3987 | miRNAWalker2 validate | -0.92 | 1.0E-5 | NA | |
| 133 | hsa-miR-200a-3p | IL1A | 0.09 | 0.93558 | -0.44 | 0.3987 | MirTarget | -0.46 | 7.0E-5 | NA | |
| 134 | hsa-miR-30a-5p | IL1A | 0.28 | 0.86479 | -0.44 | 0.3987 | MirTarget | -0.52 | 2.0E-5 | NA | |
| 135 | hsa-miR-30c-5p | IL1A | 0.03 | 0.9773 | -0.44 | 0.3987 | MirTarget | -0.49 | 0.03818 | NA | |
| 136 | hsa-miR-30d-5p | IL1A | 0.01 | 0.99569 | -0.44 | 0.3987 | MirTarget | -0.66 | 0.02066 | NA | |
| 137 | hsa-miR-30e-5p | IL1A | -0 | 0.99951 | -0.44 | 0.3987 | MirTarget | -0.62 | 0.01866 | NA | |
| 138 | hsa-miR-532-5p | IL1A | -0.11 | 0.92893 | -0.44 | 0.3987 | MirTarget | -1.5 | 0 | NA | |
| 139 | hsa-miR-30a-3p | IL1B | 0.26 | 0.85024 | -0.26 | 0.57666 | MirTarget | -0.19 | 0.01003 | NA | |
| 140 | hsa-miR-30e-3p | IL1B | 0.04 | 0.97717 | -0.26 | 0.57666 | MirTarget | -0.39 | 0.01046 | NA | |
| 141 | hsa-miR-130b-5p | IL1R1 | 0.01 | 0.98469 | 0 | 0.99459 | mirMAP | -0.15 | 0.01171 | NA | |
| 142 | hsa-miR-17-3p | IL1R1 | 0.13 | 0.90966 | 0 | 0.99459 | mirMAP | -0.48 | 0 | NA | |
| 143 | hsa-miR-197-3p | IL1R1 | -0.07 | 0.94494 | 0 | 0.99459 | miRNAWalker2 validate | -0.2 | 0.01048 | NA | |
| 144 | hsa-miR-24-3p | IL1R1 | -0 | 0.99748 | 0 | 0.99459 | miRNATAP | -0.16 | 0.04808 | NA | |
| 145 | hsa-miR-30d-3p | IL1R1 | 0.2 | 0.47989 | 0 | 0.99459 | mirMAP | -0.22 | 0.01223 | NA | |
| 146 | hsa-miR-335-3p | IL1R1 | 0.05 | 0.95617 | 0 | 0.99459 | mirMAP | -0.22 | 1.0E-5 | NA | |
| 147 | hsa-miR-590-3p | IL1R1 | -0.14 | 0.70045 | 0 | 0.99459 | miRanda; miRNATAP | -0.15 | 0.0394 | NA | |
| 148 | hsa-miR-106a-5p | IL1RAP | -0.19 | 0.7766 | 0.16 | 0.8191 | MirTarget | -0.22 | 9.0E-5 | NA | |
| 149 | hsa-miR-107 | IL1RAP | -0.14 | 0.85595 | 0.16 | 0.8191 | miRanda | -0.36 | 0.00233 | NA | |
| 150 | hsa-miR-129-5p | IL1RAP | -0.23 | 0.4913 | 0.16 | 0.8191 | miRanda | -0.11 | 0.02359 | NA |
| Num | GO | Overlap | Size | P Value | Adj. P Value |
|---|---|---|---|---|---|
| 1 | POSITIVE REGULATION OF RESPONSE TO STIMULUS | 36 | 1929 | 4.455e-25 | 2.073e-21 |
| 2 | EXTRINSIC APOPTOTIC SIGNALING PATHWAY | 15 | 99 | 3.345e-23 | 4.854e-20 |
| 3 | CELLULAR RESPONSE TO ORGANIC SUBSTANCE | 34 | 1848 | 4.173e-23 | 4.854e-20 |
| 4 | POSITIVE REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION | 27 | 876 | 2.378e-23 | 4.854e-20 |
| 5 | POSITIVE REGULATION OF I KAPPAB KINASE NF KAPPAB SIGNALING | 17 | 179 | 1.169e-22 | 1.088e-19 |
| 6 | APOPTOTIC SIGNALING PATHWAY | 19 | 289 | 2.994e-22 | 2.314e-19 |
| 7 | POSITIVE REGULATION OF PROTEIN METABOLIC PROCESS | 31 | 1492 | 3.481e-22 | 2.314e-19 |
| 8 | REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION | 32 | 1656 | 4.404e-22 | 2.562e-19 |
| 9 | INTRACELLULAR SIGNAL TRANSDUCTION | 31 | 1572 | 1.636e-21 | 8.458e-19 |
| 10 | REGULATION OF I KAPPAB KINASE NF KAPPAB SIGNALING | 17 | 233 | 1.138e-20 | 5.295e-18 |
| 11 | POSITIVE REGULATION OF CELL COMMUNICATION | 30 | 1532 | 1.326e-20 | 5.61e-18 |
| 12 | CELL DEATH | 26 | 1001 | 1.589e-20 | 6.163e-18 |
| 13 | EXTRINSIC APOPTOTIC SIGNALING PATHWAY VIA DEATH DOMAIN RECEPTORS | 11 | 39 | 1.877e-20 | 6.718e-18 |
| 14 | POSITIVE REGULATION OF MOLECULAR FUNCTION | 31 | 1791 | 7.593e-20 | 2.524e-17 |
| 15 | REGULATION OF CELL DEATH | 28 | 1472 | 1.108e-18 | 3.437e-16 |
| 16 | CYTOKINE MEDIATED SIGNALING PATHWAY | 19 | 452 | 1.412e-18 | 4.107e-16 |
| 17 | POSITIVE REGULATION OF CATALYTIC ACTIVITY | 28 | 1518 | 2.496e-18 | 6.831e-16 |
| 18 | POSITIVE REGULATION OF PROTEIN MODIFICATION PROCESS | 25 | 1135 | 5.963e-18 | 1.542e-15 |
| 19 | NEGATIVE REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY | 12 | 98 | 1.677e-17 | 4.108e-15 |
| 20 | IMMUNE SYSTEM PROCESS | 30 | 1984 | 1.957e-17 | 4.542e-15 |
| 21 | RESPONSE TO CYTOKINE | 21 | 714 | 2.05e-17 | 4.542e-15 |
| 22 | RESPONSE TO OXYGEN CONTAINING COMPOUND | 26 | 1381 | 4.524e-17 | 9.569e-15 |
| 23 | NEGATIVE REGULATION OF CELL DEATH | 22 | 872 | 7.061e-17 | 1.429e-14 |
| 24 | POSITIVE REGULATION OF PHOSPHATE METABOLIC PROCESS | 23 | 1036 | 1.774e-16 | 3.174e-14 |
| 25 | POSITIVE REGULATION OF PHOSPHORUS METABOLIC PROCESS | 23 | 1036 | 1.774e-16 | 3.174e-14 |
| 26 | REGULATION OF PHOSPHORUS METABOLIC PROCESS | 27 | 1618 | 1.736e-16 | 3.174e-14 |
| 27 | ACTIVATION OF PROTEIN KINASE ACTIVITY | 15 | 279 | 2.856e-16 | 4.921e-14 |
| 28 | CELLULAR RESPONSE TO CYTOKINE STIMULUS | 19 | 606 | 3.197e-16 | 5.312e-14 |
| 29 | REGULATION OF PROTEIN MODIFICATION PROCESS | 27 | 1710 | 6.931e-16 | 1.112e-13 |
| 30 | ACTIVATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY | 11 | 95 | 7.869e-16 | 1.22e-13 |
| 31 | REGULATION OF KINASE ACTIVITY | 20 | 776 | 1.837e-15 | 2.758e-13 |
| 32 | POSITIVE REGULATION OF KINASE ACTIVITY | 17 | 482 | 2.382e-15 | 3.464e-13 |
| 33 | REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY | 12 | 153 | 4.114e-15 | 5.801e-13 |
| 34 | ZYMOGEN ACTIVATION | 11 | 112 | 5.121e-15 | 7.009e-13 |
| 35 | REGULATION OF TRANSFERASE ACTIVITY | 21 | 946 | 5.685e-15 | 7.558e-13 |
| 36 | REGULATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY | 13 | 213 | 6.913e-15 | 8.935e-13 |
| 37 | REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY | 16 | 470 | 3.201e-14 | 4.026e-12 |
| 38 | CELLULAR RESPONSE TO OXYGEN CONTAINING COMPOUND | 19 | 799 | 4.793e-14 | 5.869e-12 |
| 39 | NEGATIVE REGULATION OF APOPTOTIC SIGNALING PATHWAY | 12 | 200 | 1.043e-13 | 1.245e-11 |
| 40 | PROTEIN MATURATION | 13 | 265 | 1.159e-13 | 1.348e-11 |
| 41 | POSITIVE REGULATION OF TRANSFERASE ACTIVITY | 17 | 616 | 1.308e-13 | 1.485e-11 |
| 42 | I KAPPAB KINASE NF KAPPAB SIGNALING | 9 | 70 | 1.509e-13 | 1.672e-11 |
| 43 | RESPONSE TO NITROGEN COMPOUND | 19 | 859 | 1.747e-13 | 1.89e-11 |
| 44 | POSITIVE REGULATION OF PEPTIDASE ACTIVITY | 11 | 154 | 1.81e-13 | 1.914e-11 |
| 45 | ACTIVATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY INVOLVED IN APOPTOTIC SIGNALING PATHWAY | 6 | 13 | 3.879e-13 | 4.011e-11 |
| 46 | TUMOR NECROSIS FACTOR MEDIATED SIGNALING PATHWAY | 10 | 118 | 4.453e-13 | 4.504e-11 |
| 47 | POSITIVE REGULATION OF IMMUNE RESPONSE | 16 | 563 | 5.112e-13 | 5.061e-11 |
| 48 | PROTEIN PHOSPHORYLATION | 19 | 944 | 9.3e-13 | 8.831e-11 |
| 49 | PHOSPHORYLATION | 21 | 1228 | 9.249e-13 | 8.831e-11 |
| 50 | REGULATION OF IMMUNE SYSTEM PROCESS | 22 | 1403 | 1.224e-12 | 1.14e-10 |
| 51 | POSITIVE REGULATION OF NF KAPPAB TRANSCRIPTION FACTOR ACTIVITY | 10 | 132 | 1.388e-12 | 1.266e-10 |
| 52 | POSITIVE REGULATION OF CELL DEATH | 16 | 605 | 1.526e-12 | 1.365e-10 |
| 53 | CELLULAR RESPONSE TO NITROGEN COMPOUND | 15 | 505 | 1.671e-12 | 1.467e-10 |
| 54 | REGULATION OF IMMUNE RESPONSE | 18 | 858 | 2.19e-12 | 1.887e-10 |
| 55 | NEGATIVE REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY VIA DEATH DOMAIN RECEPTORS | 7 | 34 | 2.69e-12 | 2.276e-10 |
| 56 | POSITIVE REGULATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY INVOLVED IN APOPTOTIC SIGNALING PATHWAY | 6 | 17 | 2.776e-12 | 2.306e-10 |
| 57 | REGULATION OF RESPONSE TO CYTOKINE STIMULUS | 10 | 144 | 3.336e-12 | 2.723e-10 |
| 58 | INTRINSIC APOPTOTIC SIGNALING PATHWAY | 10 | 152 | 5.739e-12 | 4.604e-10 |
| 59 | REGULATION OF APOPTOTIC SIGNALING PATHWAY | 13 | 363 | 6.281e-12 | 4.953e-10 |
| 60 | POSITIVE REGULATION OF SEQUENCE SPECIFIC DNA BINDING TRANSCRIPTION FACTOR ACTIVITY | 11 | 228 | 1.33e-11 | 1.03e-09 |
| 61 | IMMUNE RESPONSE | 19 | 1100 | 1.351e-11 | 1.03e-09 |
| 62 | REGULATION OF PEPTIDASE ACTIVITY | 13 | 392 | 1.644e-11 | 1.224e-09 |
| 63 | REGULATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY INVOLVED IN APOPTOTIC SIGNALING PATHWAY | 6 | 22 | 1.657e-11 | 1.224e-09 |
| 64 | REGULATION OF PROTEOLYSIS | 16 | 711 | 1.73e-11 | 1.258e-09 |
| 65 | REGULATION OF MAP KINASE ACTIVITY | 12 | 319 | 2.573e-11 | 1.842e-09 |
| 66 | REGULATION OF RESPONSE TO STRESS | 21 | 1468 | 2.769e-11 | 1.952e-09 |
| 67 | POSITIVE REGULATION OF IMMUNE SYSTEM PROCESS | 17 | 867 | 3.036e-11 | 2.108e-09 |
| 68 | PHOSPHATIDYLINOSITOL 3 PHOSPHATE BIOSYNTHETIC PROCESS | 7 | 49 | 4.17e-11 | 2.853e-09 |
| 69 | ACTIVATION OF IMMUNE RESPONSE | 13 | 427 | 4.764e-11 | 3.212e-09 |
| 70 | REGULATION OF TUMOR NECROSIS FACTOR MEDIATED SIGNALING PATHWAY | 7 | 50 | 4.839e-11 | 3.217e-09 |
| 71 | REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY VIA DEATH DOMAIN RECEPTORS | 7 | 55 | 9.735e-11 | 6.38e-09 |
| 72 | INFLAMMATORY RESPONSE | 13 | 454 | 1.017e-10 | 6.572e-09 |
| 73 | POSITIVE REGULATION OF PROTEOLYSIS | 12 | 363 | 1.146e-10 | 7.305e-09 |
| 74 | POSITIVE REGULATION OF DEFENSE RESPONSE | 12 | 364 | 1.183e-10 | 7.438e-09 |
| 75 | INTERLEUKIN 1 MEDIATED SIGNALING PATHWAY | 5 | 13 | 1.235e-10 | 7.665e-09 |
| 76 | PHOSPHATE CONTAINING COMPOUND METABOLIC PROCESS | 23 | 1977 | 1.396e-10 | 8.545e-09 |
| 77 | POSITIVE REGULATION OF MAPK CASCADE | 13 | 470 | 1.558e-10 | 9.416e-09 |
| 78 | NEURON APOPTOTIC PROCESS | 6 | 35 | 3.513e-10 | 2.096e-08 |
| 79 | RESPONSE TO TUMOR NECROSIS FACTOR | 10 | 233 | 3.914e-10 | 2.305e-08 |
| 80 | RESPONSE TO MOLECULE OF BACTERIAL ORIGIN | 11 | 321 | 5.159e-10 | 3.001e-08 |
| 81 | POSITIVE REGULATION OF APOPTOTIC SIGNALING PATHWAY | 9 | 171 | 5.304e-10 | 3.047e-08 |
| 82 | PHOSPHATIDYLINOSITOL BIOSYNTHETIC PROCESS | 8 | 120 | 8.007e-10 | 4.544e-08 |
| 83 | REGULATION OF NEURON DEATH | 10 | 252 | 8.389e-10 | 4.703e-08 |
| 84 | REGULATION OF MAPK CASCADE | 14 | 660 | 8.79e-10 | 4.869e-08 |
| 85 | RESPONSE TO WOUNDING | 13 | 563 | 1.411e-09 | 7.723e-08 |
| 86 | RESPONSE TO ENDOGENOUS STIMULUS | 19 | 1450 | 1.494e-09 | 8.081e-08 |
| 87 | REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY IN ABSENCE OF LIGAND | 6 | 46 | 1.984e-09 | 1.053e-07 |
| 88 | REGULATION OF SEQUENCE SPECIFIC DNA BINDING TRANSCRIPTION FACTOR ACTIVITY | 11 | 365 | 1.991e-09 | 1.053e-07 |
| 89 | WOUND HEALING | 12 | 470 | 2.171e-09 | 1.135e-07 |
| 90 | TOLL LIKE RECEPTOR SIGNALING PATHWAY | 7 | 85 | 2.232e-09 | 1.154e-07 |
| 91 | NEURON DEATH | 6 | 47 | 2.27e-09 | 1.161e-07 |
| 92 | REGULATION OF CELL PROLIFERATION | 19 | 1496 | 2.512e-09 | 1.271e-07 |
| 93 | POSITIVE REGULATION OF MAP KINASE ACTIVITY | 9 | 207 | 2.867e-09 | 1.434e-07 |
| 94 | HOMEOSTATIC PROCESS | 18 | 1337 | 3.05e-09 | 1.51e-07 |
| 95 | POSITIVE REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY | 10 | 289 | 3.147e-09 | 1.541e-07 |
| 96 | CHEMICAL HOMEOSTASIS | 15 | 874 | 3.541e-09 | 1.716e-07 |
| 97 | RESPONSE TO ABIOTIC STIMULUS | 16 | 1024 | 3.603e-09 | 1.728e-07 |
| 98 | RESPONSE TO BIOTIC STIMULUS | 15 | 886 | 4.258e-09 | 2.022e-07 |
| 99 | PHOSPHATIDYLINOSITOL 3 KINASE SIGNALING | 5 | 25 | 4.981e-09 | 2.341e-07 |
| 100 | REGULATION OF DEFENSE RESPONSE | 14 | 759 | 5.287e-09 | 2.44e-07 |
| 101 | CELLULAR RESPONSE TO STRESS | 19 | 1565 | 5.297e-09 | 2.44e-07 |
| 102 | RESPONSE TO EXTERNAL STIMULUS | 20 | 1821 | 1.002e-08 | 4.571e-07 |
| 103 | PATTERN RECOGNITION RECEPTOR SIGNALING PATHWAY | 7 | 109 | 1.285e-08 | 5.804e-07 |
| 104 | NEGATIVE REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY IN ABSENCE OF LIGAND | 5 | 32 | 1.862e-08 | 8.175e-07 |
| 105 | INTRINSIC APOPTOTIC SIGNALING PATHWAY IN RESPONSE TO ENDOPLASMIC RETICULUM STRESS | 5 | 32 | 1.862e-08 | 8.175e-07 |
| 106 | NEGATIVE REGULATION OF SIGNAL TRANSDUCTION IN ABSENCE OF LIGAND | 5 | 32 | 1.862e-08 | 8.175e-07 |
| 107 | REGULATION OF ENDOTHELIAL CELL DEVELOPMENT | 4 | 12 | 1.98e-08 | 8.531e-07 |
| 108 | REGULATION OF ESTABLISHMENT OF ENDOTHELIAL BARRIER | 4 | 12 | 1.98e-08 | 8.531e-07 |
| 109 | SIGNAL TRANSDUCTION IN ABSENCE OF LIGAND | 5 | 33 | 2.191e-08 | 9.266e-07 |
| 110 | EXTRINSIC APOPTOTIC SIGNALING PATHWAY IN ABSENCE OF LIGAND | 5 | 33 | 2.191e-08 | 9.266e-07 |
| 111 | CELLULAR RESPONSE TO ENDOGENOUS STIMULUS | 15 | 1008 | 2.401e-08 | 1.006e-06 |
| 112 | INTRINSIC APOPTOTIC SIGNALING PATHWAY IN RESPONSE TO DNA DAMAGE | 6 | 71 | 2.887e-08 | 1.2e-06 |
| 113 | NEGATIVE REGULATION OF CELL COMMUNICATION | 16 | 1192 | 3.091e-08 | 1.273e-06 |
| 114 | INOSITOL LIPID MEDIATED SIGNALING | 7 | 124 | 3.151e-08 | 1.286e-06 |
| 115 | PHOSPHATIDYLINOSITOL METABOLIC PROCESS | 8 | 193 | 3.403e-08 | 1.377e-06 |
| 116 | CELLULAR GLUCOSE HOMEOSTASIS | 6 | 75 | 4.028e-08 | 1.616e-06 |
| 117 | DEFENSE RESPONSE | 16 | 1231 | 4.841e-08 | 1.925e-06 |
| 118 | ACTIVATION OF INNATE IMMUNE RESPONSE | 8 | 204 | 5.231e-08 | 2.063e-06 |
| 119 | GLYCEROLIPID BIOSYNTHETIC PROCESS | 8 | 211 | 6.79e-08 | 2.655e-06 |
| 120 | RESPONSE TO BACTERIUM | 11 | 528 | 8.877e-08 | 3.442e-06 |
| 121 | ACTIVATION OF PROTEIN KINASE A ACTIVITY | 4 | 17 | 9.429e-08 | 3.626e-06 |
| 122 | HEMOSTASIS | 9 | 311 | 9.688e-08 | 3.695e-06 |
| 123 | CELLULAR RESPONSE TO INTERLEUKIN 1 | 6 | 88 | 1.056e-07 | 3.997e-06 |
| 124 | IMMUNE RESPONSE REGULATING CELL SURFACE RECEPTOR SIGNALING PATHWAY | 9 | 323 | 1.336e-07 | 5.015e-06 |
| 125 | REGULATION OF HYDROLASE ACTIVITY | 16 | 1327 | 1.366e-07 | 5.083e-06 |
| 126 | PHOSPHOLIPID BIOSYNTHETIC PROCESS | 8 | 235 | 1.555e-07 | 5.741e-06 |
| 127 | POSITIVE REGULATION OF GENE EXPRESSION | 18 | 1733 | 1.688e-07 | 6.184e-06 |
| 128 | NEGATIVE REGULATION OF RESPONSE TO STIMULUS | 16 | 1360 | 1.911e-07 | 6.947e-06 |
| 129 | LIPID PHOSPHORYLATION | 6 | 99 | 2.138e-07 | 7.71e-06 |
| 130 | POSITIVE REGULATION OF INNATE IMMUNE RESPONSE | 8 | 246 | 2.206e-07 | 7.895e-06 |
| 131 | PROTEOLYSIS | 15 | 1208 | 2.567e-07 | 9.049e-06 |
| 132 | RENAL SYSTEM PROCESS | 6 | 102 | 2.554e-07 | 9.049e-06 |
| 133 | STRESS ACTIVATED PROTEIN KINASE SIGNALING CASCADE | 6 | 103 | 2.706e-07 | 9.467e-06 |
| 134 | RESPONSE TO LIPID | 13 | 888 | 3.032e-07 | 1.053e-05 |
| 135 | REGULATION OF INNATE IMMUNE RESPONSE | 9 | 357 | 3.112e-07 | 1.072e-05 |
| 136 | LEUKOCYTE MIGRATION | 8 | 259 | 3.265e-07 | 1.117e-05 |
| 137 | CELLULAR RESPONSE TO ABIOTIC STIMULUS | 8 | 263 | 3.668e-07 | 1.246e-05 |
| 138 | POSITIVE REGULATION OF HYDROLASE ACTIVITY | 13 | 905 | 3.764e-07 | 1.269e-05 |
| 139 | MULTICELLULAR ORGANISMAL HOMEOSTASIS | 8 | 272 | 4.734e-07 | 1.585e-05 |
| 140 | REGULATION OF CELL ADHESION | 11 | 629 | 5.102e-07 | 1.696e-05 |
| 141 | RESPONSE TO INTERLEUKIN 1 | 6 | 115 | 5.201e-07 | 1.716e-05 |
| 142 | REGULATION OF NECROTIC CELL DEATH | 4 | 26 | 5.821e-07 | 1.908e-05 |
| 143 | REGULATION OF NEURON APOPTOTIC PROCESS | 7 | 192 | 6.254e-07 | 2.035e-05 |
| 144 | REGULATION OF ENDOTHELIAL CELL DIFFERENTIATION | 4 | 27 | 6.821e-07 | 2.204e-05 |
| 145 | ANTIGEN RECEPTOR MEDIATED SIGNALING PATHWAY | 7 | 195 | 6.942e-07 | 2.228e-05 |
| 146 | REGULATION OF EPITHELIAL CELL DIFFERENTIATION | 6 | 122 | 7.368e-07 | 2.348e-05 |
| 147 | NUCLEOTIDE BINDING DOMAIN LEUCINE RICH REPEAT CONTAINING RECEPTOR SIGNALING PATHWAY | 4 | 28 | 7.942e-07 | 2.497e-05 |
| 148 | NECROTIC CELL DEATH | 4 | 28 | 7.942e-07 | 2.497e-05 |
| 149 | RESPONSE TO PEPTIDE | 9 | 404 | 8.743e-07 | 2.712e-05 |
| 150 | SIGNAL TRANSDUCTION BY PROTEIN PHOSPHORYLATION | 9 | 404 | 8.743e-07 | 2.712e-05 |
| 151 | POSITIVE REGULATION OF NIK NF KAPPAB SIGNALING | 4 | 29 | 9.195e-07 | 2.796e-05 |
| 152 | GLYCEROPHOSPHOLIPID METABOLIC PROCESS | 8 | 297 | 9.187e-07 | 2.796e-05 |
| 153 | NEGATIVE REGULATION OF CATABOLIC PROCESS | 7 | 203 | 9.093e-07 | 2.796e-05 |
| 154 | CELLULAR HOMEOSTASIS | 11 | 676 | 1.036e-06 | 3.131e-05 |
| 155 | LIPOPOLYSACCHARIDE MEDIATED SIGNALING PATHWAY | 4 | 31 | 1.214e-06 | 3.643e-05 |
| 156 | RESPONSE TO OXYGEN LEVELS | 8 | 311 | 1.298e-06 | 3.87e-05 |
| 157 | CELLULAR RESPONSE TO CARBOHYDRATE STIMULUS | 5 | 74 | 1.372e-06 | 4.066e-05 |
| 158 | MYD88 DEPENDENT TOLL LIKE RECEPTOR SIGNALING PATHWAY | 4 | 32 | 1.384e-06 | 4.076e-05 |
| 159 | ACTIVATION OF MAPK ACTIVITY | 6 | 137 | 1.454e-06 | 4.256e-05 |
| 160 | CYTOPLASMIC PATTERN RECOGNITION RECEPTOR SIGNALING PATHWAY | 4 | 33 | 1.572e-06 | 4.572e-05 |
| 161 | CELL ACTIVATION | 10 | 568 | 1.705e-06 | 4.927e-05 |
| 162 | CELLULAR CHEMICAL HOMEOSTASIS | 10 | 570 | 1.76e-06 | 5.054e-05 |
| 163 | RENAL WATER HOMEOSTASIS | 4 | 34 | 1.778e-06 | 5.076e-05 |
| 164 | FC EPSILON RECEPTOR SIGNALING PATHWAY | 6 | 142 | 1.793e-06 | 5.087e-05 |
| 165 | CELLULAR RESPONSE TO MECHANICAL STIMULUS | 5 | 80 | 2.024e-06 | 5.707e-05 |
| 166 | T CELL RECEPTOR SIGNALING PATHWAY | 6 | 146 | 2.108e-06 | 5.908e-05 |
| 167 | REGULATION OF CATABOLIC PROCESS | 11 | 731 | 2.218e-06 | 6.178e-05 |
| 168 | JNK CASCADE | 5 | 82 | 2.288e-06 | 6.337e-05 |
| 169 | RESPONSE TO HORMONE | 12 | 893 | 2.309e-06 | 6.357e-05 |
| 170 | NIK NF KAPPAB SIGNALING | 5 | 83 | 2.43e-06 | 6.651e-05 |
| 171 | NEGATIVE REGULATION OF MOLECULAR FUNCTION | 13 | 1079 | 2.708e-06 | 7.368e-05 |
| 172 | CELLULAR RESPONSE TO GLUCAGON STIMULUS | 4 | 38 | 2.809e-06 | 7.599e-05 |
| 173 | RESPONSE TO INORGANIC SUBSTANCE | 9 | 479 | 3.545e-06 | 9.48e-05 |
| 174 | GLYCEROLIPID METABOLIC PROCESS | 8 | 356 | 3.541e-06 | 9.48e-05 |
| 175 | REGULATION OF CELL ACTIVATION | 9 | 484 | 3.857e-06 | 0.0001026 |
| 176 | LEUKOCYTE CELL CELL ADHESION | 7 | 255 | 4.137e-06 | 0.0001094 |
| 177 | PHOSPHOLIPID METABOLIC PROCESS | 8 | 364 | 4.171e-06 | 0.0001097 |
| 178 | REGULATION OF NIK NF KAPPAB SIGNALING | 4 | 42 | 4.227e-06 | 0.0001105 |
| 179 | HEPATOCYTE APOPTOTIC PROCESS | 3 | 13 | 4.655e-06 | 0.000121 |
| 180 | GLUCOSE HOMEOSTASIS | 6 | 170 | 5.084e-06 | 0.0001307 |
| 181 | CARBOHYDRATE HOMEOSTASIS | 6 | 170 | 5.084e-06 | 0.0001307 |
| 182 | CELLULAR RESPONSE TO EXTERNAL STIMULUS | 7 | 264 | 5.196e-06 | 0.0001328 |
| 183 | NEGATIVE REGULATION OF NEURON DEATH | 6 | 171 | 5.259e-06 | 0.0001337 |
| 184 | REGULATION OF BODY FLUID LEVELS | 9 | 506 | 5.53e-06 | 0.0001398 |
| 185 | TOLL LIKE RECEPTOR 9 SIGNALING PATHWAY | 3 | 14 | 5.913e-06 | 0.0001479 |
| 186 | REGULATION OF CAMP DEPENDENT PROTEIN KINASE ACTIVITY | 3 | 14 | 5.913e-06 | 0.0001479 |
| 187 | CELLULAR RESPONSE TO PEPTIDE | 7 | 274 | 6.628e-06 | 0.0001649 |
| 188 | RESPONSE TO GLUCAGON | 4 | 48 | 7.264e-06 | 0.0001798 |
| 189 | POSITIVE REGULATION OF PROTEIN IMPORT | 5 | 104 | 7.386e-06 | 0.0001818 |
| 190 | REGULATION OF LIPID METABOLIC PROCESS | 7 | 282 | 7.998e-06 | 0.0001959 |
| 191 | POSITIVE REGULATION OF BIOSYNTHETIC PROCESS | 16 | 1805 | 8.09e-06 | 0.0001971 |
| 192 | RESPONSE TO GAMMA RADIATION | 4 | 50 | 8.564e-06 | 0.0002075 |
| 193 | NEGATIVE REGULATION OF CELLULAR COMPONENT ORGANIZATION | 10 | 684 | 8.844e-06 | 0.0002132 |
| 194 | POSITIVE REGULATION OF TRANSCRIPTION FACTOR IMPORT INTO NUCLEUS | 4 | 51 | 9.275e-06 | 0.0002225 |
| 195 | RESPONSE TO REACTIVE OXYGEN SPECIES | 6 | 191 | 9.909e-06 | 0.0002364 |
| 196 | LEUKOCYTE DIFFERENTIATION | 7 | 292 | 1.003e-05 | 0.0002382 |
| 197 | REGULATION OF INFLAMMATORY RESPONSE | 7 | 294 | 1.049e-05 | 0.0002477 |
| 198 | RESPONSE TO AMINO ACID | 5 | 112 | 1.061e-05 | 0.0002493 |
| 199 | CELLULAR RESPONSE TO AMINO ACID STIMULUS | 4 | 53 | 1.083e-05 | 0.0002531 |
| 200 | ACTIVATION OF NF KAPPAB INDUCING KINASE ACTIVITY | 3 | 17 | 1.099e-05 | 0.0002543 |
| 201 | NEGATIVE REGULATION OF ANOIKIS | 3 | 17 | 1.099e-05 | 0.0002543 |
| 202 | CELLULAR RESPONSE TO HORMONE STIMULUS | 9 | 552 | 1.112e-05 | 0.0002562 |
| 203 | REGULATION OF MULTICELLULAR ORGANISMAL DEVELOPMENT | 15 | 1672 | 1.469e-05 | 0.0003367 |
| 204 | FC RECEPTOR SIGNALING PATHWAY | 6 | 206 | 1.523e-05 | 0.0003474 |
| 205 | POSITIVE REGULATION OF NUCLEOCYTOPLASMIC TRANSPORT | 5 | 121 | 1.544e-05 | 0.0003505 |
| 206 | MULTICELLULAR ORGANISMAL WATER HOMEOSTASIS | 4 | 58 | 1.554e-05 | 0.0003509 |
| 207 | LIPID MODIFICATION | 6 | 210 | 1.698e-05 | 0.0003817 |
| 208 | RESPONSE TO ACID CHEMICAL | 7 | 319 | 1.777e-05 | 0.0003976 |
| 209 | CELLULAR LIPID METABOLIC PROCESS | 11 | 913 | 1.828e-05 | 0.0004069 |
| 210 | NEGATIVE REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY | 5 | 126 | 1.879e-05 | 0.0004163 |
| 211 | ORGANOPHOSPHATE BIOSYNTHETIC PROCESS | 8 | 450 | 1.95e-05 | 0.0004299 |
| 212 | NECROPTOTIC PROCESS | 3 | 21 | 2.133e-05 | 0.0004616 |
| 213 | POSITIVE REGULATION OF PROTEIN LOCALIZATION TO NUCLEUS | 5 | 129 | 2.105e-05 | 0.0004616 |
| 214 | NEGATIVE REGULATION OF LIPID CATABOLIC PROCESS | 3 | 21 | 2.133e-05 | 0.0004616 |
| 215 | RESPONSE TO NITRIC OXIDE | 3 | 21 | 2.133e-05 | 0.0004616 |
| 216 | SINGLE ORGANISM CELL ADHESION | 8 | 459 | 2.247e-05 | 0.000484 |
| 217 | POSITIVE REGULATION OF NEURON DEATH | 4 | 67 | 2.759e-05 | 0.0005916 |
| 218 | LYMPHOCYTE ACTIVATION | 7 | 342 | 2.777e-05 | 0.0005928 |
| 219 | RESPONSE TO ENDOPLASMIC RETICULUM STRESS | 6 | 233 | 3.049e-05 | 0.0006479 |
| 220 | REGULATION OF ANOIKIS | 3 | 24 | 3.228e-05 | 0.0006797 |
| 221 | REGULATION OF EXECUTION PHASE OF APOPTOSIS | 3 | 24 | 3.228e-05 | 0.0006797 |
| 222 | WATER HOMEOSTASIS | 4 | 70 | 3.281e-05 | 0.0006877 |
| 223 | PLATELET ACTIVATION | 5 | 142 | 3.341e-05 | 0.0006971 |
| 224 | IMMUNE EFFECTOR PROCESS | 8 | 486 | 3.377e-05 | 0.0007014 |
| 225 | CELLULAR EXTRAVASATION | 3 | 25 | 3.662e-05 | 0.0007539 |
| 226 | EPITHELIAL CELL APOPTOTIC PROCESS | 3 | 25 | 3.662e-05 | 0.0007539 |
| 227 | REGULATION OF ORGANELLE ORGANIZATION | 12 | 1178 | 3.783e-05 | 0.0007754 |
| 228 | POSITIVE REGULATION OF CELL CELL ADHESION | 6 | 243 | 3.858e-05 | 0.0007873 |
| 229 | POSITIVE REGULATION OF CELL PROLIFERATION | 10 | 814 | 3.952e-05 | 0.0008029 |
| 230 | PEPTIDYL SERINE MODIFICATION | 5 | 148 | 4.073e-05 | 0.0008239 |
| 231 | DEVELOPMENTAL PROGRAMMED CELL DEATH | 3 | 26 | 4.132e-05 | 0.0008323 |
| 232 | RESPONSE TO VIRUS | 6 | 247 | 4.225e-05 | 0.0008475 |
| 233 | GRANULOCYTE MIGRATION | 4 | 75 | 4.308e-05 | 0.0008603 |
| 234 | NEGATIVE REGULATION OF CATALYTIC ACTIVITY | 10 | 829 | 4.611e-05 | 0.0009169 |
| 235 | POSITIVE REGULATION OF ACUTE INFLAMMATORY RESPONSE | 3 | 28 | 5.187e-05 | 0.001027 |
| 236 | REGULATION OF CELL CELL ADHESION | 7 | 380 | 5.42e-05 | 0.001069 |
| 237 | MUSCLE ADAPTATION | 3 | 29 | 5.775e-05 | 0.001134 |
| 238 | AGING | 6 | 264 | 6.116e-05 | 0.001196 |
| 239 | MYD88 INDEPENDENT TOLL LIKE RECEPTOR SIGNALING PATHWAY | 3 | 30 | 6.405e-05 | 0.001247 |
| 240 | CELLULAR RESPONSE TO BIOTIC STIMULUS | 5 | 163 | 6.45e-05 | 0.00125 |
| 241 | LIPID BIOSYNTHETIC PROCESS | 8 | 539 | 7e-05 | 0.001352 |
| 242 | POSITIVE REGULATION OF INTERLEUKIN 2 PRODUCTION | 3 | 31 | 7.078e-05 | 0.001361 |
| 243 | RESPONSE TO CARBOHYDRATE | 5 | 168 | 7.442e-05 | 0.001425 |
| 244 | RESPONSE TO HEAT | 4 | 89 | 8.425e-05 | 0.001607 |
| 245 | NEGATIVE REGULATION OF PROTEIN METABOLIC PROCESS | 11 | 1087 | 8.972e-05 | 0.001704 |
| 246 | CELLULAR RESPONSE TO ACID CHEMICAL | 5 | 175 | 9.025e-05 | 0.001707 |
| 247 | REGULATION OF RESPONSE TO WOUNDING | 7 | 413 | 9.135e-05 | 0.001721 |
| 248 | LEUKOCYTE ACTIVATION | 7 | 414 | 9.274e-05 | 0.001733 |
| 249 | RESPONSE TO CORTICOSTEROID | 5 | 176 | 9.271e-05 | 0.001733 |
| 250 | PROTEIN KINASE B SIGNALING | 3 | 34 | 9.371e-05 | 0.001744 |
| 251 | REGULATION OF CYTOKINE PRODUCTION | 8 | 563 | 9.481e-05 | 0.001757 |
| 252 | RESPONSE TO ORGANIC CYCLIC COMPOUND | 10 | 917 | 0.000107 | 0.001976 |
| 253 | REGULATION OF TRANSCRIPTION FACTOR IMPORT INTO NUCLEUS | 4 | 95 | 0.0001086 | 0.001997 |
| 254 | REGULATION OF PROTEIN IMPORT | 5 | 183 | 0.0001114 | 0.00204 |
| 255 | FEMALE GAMETE GENERATION | 4 | 96 | 0.0001131 | 0.002064 |
| 256 | IMMUNE SYSTEM DEVELOPMENT | 8 | 582 | 0.0001193 | 0.002168 |
| 257 | MYELOID LEUKOCYTE MIGRATION | 4 | 99 | 0.0001274 | 0.002307 |
| 258 | PROTEIN COMPLEX BIOGENESIS | 11 | 1132 | 0.0001287 | 0.002312 |
| 259 | PROTEIN COMPLEX ASSEMBLY | 11 | 1132 | 0.0001287 | 0.002312 |
| 260 | REGULATION OF GLUCOSE TRANSPORT | 4 | 100 | 0.0001325 | 0.002371 |
| 261 | REGULATION OF HOMOTYPIC CELL CELL ADHESION | 6 | 307 | 0.0001401 | 0.002497 |
| 262 | POSITIVE REGULATION OF CELL ACTIVATION | 6 | 311 | 0.0001503 | 0.002669 |
| 263 | ANATOMICAL STRUCTURE FORMATION INVOLVED IN MORPHOGENESIS | 10 | 957 | 0.0001519 | 0.002688 |
| 264 | REGULATION OF PHOSPHATIDYLINOSITOL 3 KINASE ACTIVITY | 3 | 40 | 0.000153 | 0.002697 |
| 265 | LIPID METABOLIC PROCESS | 11 | 1158 | 0.0001572 | 0.00276 |
| 266 | CELL CELL ADHESION | 8 | 608 | 0.000161 | 0.002817 |
| 267 | MYELOID LEUKOCYTE MEDIATED IMMUNITY | 3 | 43 | 0.0001901 | 0.003313 |
| 268 | POSITIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS | 12 | 1395 | 0.000191 | 0.003315 |
| 269 | LYMPHOCYTE DIFFERENTIATION | 5 | 209 | 0.0002071 | 0.003583 |
| 270 | POSITIVE REGULATION OF INFLAMMATORY RESPONSE | 4 | 113 | 0.0002122 | 0.003643 |
| 271 | RESPONSE TO MECHANICAL STIMULUS | 5 | 210 | 0.0002118 | 0.003643 |
| 272 | CELL DEVELOPMENT | 12 | 1426 | 0.0002343 | 0.004009 |
| 273 | POSITIVE REGULATION OF NEURON APOPTOTIC PROCESS | 3 | 47 | 0.0002479 | 0.004226 |
| 274 | REGULATION OF PROTEIN LOCALIZATION TO NUCLEUS | 5 | 218 | 0.0002518 | 0.004276 |
| 275 | REGULATION OF NUCLEOCYTOPLASMIC TRANSPORT | 5 | 220 | 0.0002626 | 0.004434 |
| 276 | REGULATION OF LIPID KINASE ACTIVITY | 3 | 48 | 0.000264 | 0.004434 |
| 277 | REGULATION OF INTERLEUKIN 2 PRODUCTION | 3 | 48 | 0.000264 | 0.004434 |
| 278 | CYTOKINE PRODUCTION | 4 | 120 | 0.0002671 | 0.004471 |
| 279 | CELL MOTILITY | 9 | 835 | 0.0002702 | 0.00449 |
| 280 | LOCALIZATION OF CELL | 9 | 835 | 0.0002702 | 0.00449 |
| 281 | RESPONSE TO OXIDATIVE STRESS | 6 | 352 | 0.000293 | 0.004852 |
| 282 | CELL PROLIFERATION | 8 | 672 | 0.0003174 | 0.005237 |
| 283 | POSITIVE REGULATION OF CELLULAR PROTEIN LOCALIZATION | 6 | 360 | 0.0003304 | 0.005432 |
| 284 | REGULATION OF LIPID CATABOLIC PROCESS | 3 | 52 | 0.0003348 | 0.005486 |
| 285 | POSITIVE REGULATION OF ESTABLISHMENT OF PROTEIN LOCALIZATION | 7 | 514 | 0.0003494 | 0.005705 |
| 286 | REGULATION OF CERAMIDE BIOSYNTHETIC PROCESS | 2 | 11 | 0.0003592 | 0.005744 |
| 287 | POSITIVE REGULATION OF HAIR CYCLE | 2 | 11 | 0.0003592 | 0.005744 |
| 288 | REGULATION OF FEVER GENERATION | 2 | 11 | 0.0003592 | 0.005744 |
| 289 | POSITIVE REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY | 3 | 53 | 0.0003543 | 0.005744 |
| 290 | REGULATION OF NECROPTOTIC PROCESS | 2 | 11 | 0.0003592 | 0.005744 |
| 291 | POSITIVE REGULATION OF NFAT PROTEIN IMPORT INTO NUCLEUS | 2 | 11 | 0.0003592 | 0.005744 |
| 292 | POSITIVE REGULATION OF INTRACELLULAR TRANSPORT | 6 | 370 | 0.0003823 | 0.006053 |
| 293 | POSITIVE REGULATION OF CYTOKINE PRODUCTION | 6 | 370 | 0.0003823 | 0.006053 |
| 294 | REGULATION OF CELLULAR RESPONSE TO STRESS | 8 | 691 | 0.0003825 | 0.006053 |
| 295 | B CELL ACTIVATION | 4 | 132 | 0.000384 | 0.006057 |
| 296 | NEGATIVE REGULATION OF IMMUNE SYSTEM PROCESS | 6 | 372 | 0.0003934 | 0.006183 |
| 297 | EXECUTION PHASE OF APOPTOSIS | 3 | 55 | 0.0003953 | 0.006193 |
| 298 | RESPONSE TO TOXIC SUBSTANCE | 5 | 241 | 0.0003992 | 0.006234 |
| 299 | NEGATIVE REGULATION OF NEURON APOPTOTIC PROCESS | 4 | 135 | 0.0004181 | 0.006464 |
| 300 | POSITIVE REGULATION OF STRESS ACTIVATED PROTEIN KINASE SIGNALING CASCADE | 4 | 135 | 0.0004181 | 0.006464 |
| 301 | POSITIVE REGULATION OF CELL ADHESION | 6 | 376 | 0.0004163 | 0.006464 |
| 302 | REGULATION OF VITAMIN METABOLIC PROCESS | 2 | 12 | 0.0004304 | 0.006566 |
| 303 | REGULATION OF CHEMOKINE BIOSYNTHETIC PROCESS | 2 | 12 | 0.0004304 | 0.006566 |
| 304 | POSITIVE REGULATION OF INTERLEUKIN 2 BIOSYNTHETIC PROCESS | 2 | 12 | 0.0004304 | 0.006566 |
| 305 | POSITIVE REGULATION OF GLUCOSE IMPORT IN RESPONSE TO INSULIN STIMULUS | 2 | 12 | 0.0004304 | 0.006566 |
| 306 | REGULATION OF CYTOKINE PRODUCTION INVOLVED IN IMMUNE RESPONSE | 3 | 57 | 0.0004393 | 0.006658 |
| 307 | PROTEIN COMPLEX SUBUNIT ORGANIZATION | 12 | 1527 | 0.0004392 | 0.006658 |
| 308 | RESPONSE TO ALKALOID | 4 | 137 | 0.0004421 | 0.006679 |
| 309 | EMBRYO DEVELOPMENT | 9 | 894 | 0.0004458 | 0.006714 |
| 310 | REGULATION OF PHOSPHATIDYLINOSITOL 3 KINASE SIGNALING | 4 | 138 | 0.0004544 | 0.006821 |
| 311 | REGULATION OF AUTOPHAGY | 5 | 249 | 0.0004634 | 0.006911 |
| 312 | POSITIVE REGULATION OF CYTOKINE BIOSYNTHETIC PROCESS | 3 | 58 | 0.0004624 | 0.006911 |
| 313 | NEGATIVE REGULATION OF KINASE ACTIVITY | 5 | 250 | 0.0004719 | 0.007015 |
| 314 | NEGATIVE REGULATION OF PHOSPHORUS METABOLIC PROCESS | 7 | 541 | 0.000475 | 0.007016 |
| 315 | NEGATIVE REGULATION OF PHOSPHATE METABOLIC PROCESS | 7 | 541 | 0.000475 | 0.007016 |
| 316 | REGULATION OF CELLULAR RESPONSE TO INSULIN STIMULUS | 3 | 59 | 0.0004863 | 0.00716 |
| 317 | CELLULAR PROCESS INVOLVED IN REPRODUCTION IN MULTICELLULAR ORGANISM | 5 | 252 | 0.0004893 | 0.007183 |
| 318 | REGULATION OF SPHINGOLIPID BIOSYNTHETIC PROCESS | 2 | 13 | 0.0005078 | 0.007292 |
| 319 | REGULATION OF MEMBRANE LIPID METABOLIC PROCESS | 2 | 13 | 0.0005078 | 0.007292 |
| 320 | POSITIVE REGULATION OF STEROID BIOSYNTHETIC PROCESS | 2 | 13 | 0.0005078 | 0.007292 |
| 321 | REGULATION OF HISTONE PHOSPHORYLATION | 2 | 13 | 0.0005078 | 0.007292 |
| 322 | PROTEIN AUTOPROCESSING | 2 | 13 | 0.0005078 | 0.007292 |
| 323 | CELLULAR RESPONSE TO DNA DAMAGE STIMULUS | 8 | 720 | 0.0005026 | 0.007292 |
| 324 | REGULATION OF BICELLULAR TIGHT JUNCTION ASSEMBLY | 2 | 13 | 0.0005078 | 0.007292 |
| 325 | REGULATION OF GLUCOSE IMPORT | 3 | 60 | 0.0005109 | 0.007293 |
| 326 | POSITIVE REGULATION OF SMOOTH MUSCLE CELL PROLIFERATION | 3 | 60 | 0.0005109 | 0.007293 |
| 327 | CELLULAR RESPONSE TO OXYGEN LEVELS | 4 | 143 | 0.0005198 | 0.007396 |
| 328 | REGULATION OF PHOSPHOLIPID METABOLIC PROCESS | 3 | 61 | 0.0005364 | 0.007586 |
| 329 | REGULATION OF CELLULAR PROTEIN LOCALIZATION | 7 | 552 | 0.0005355 | 0.007586 |
| 330 | POSITIVE REGULATION OF INTRACELLULAR PROTEIN TRANSPORT | 5 | 258 | 0.0005445 | 0.007678 |
| 331 | RESPONSE TO IONIZING RADIATION | 4 | 145 | 0.0005477 | 0.007699 |
| 332 | REGULATION OF FIBROBLAST APOPTOTIC PROCESS | 2 | 14 | 0.0005914 | 0.008216 |
| 333 | T CELL MIGRATION | 2 | 14 | 0.0005914 | 0.008216 |
| 334 | RESPONSE TO TEMPERATURE STIMULUS | 4 | 148 | 0.0005915 | 0.008216 |
| 335 | POSITIVE REGULATION OF JUN KINASE ACTIVITY | 3 | 63 | 0.0005897 | 0.008216 |
| 336 | NEGATIVE REGULATION OF PHOSPHOPROTEIN PHOSPHATASE ACTIVITY | 2 | 15 | 0.0006813 | 0.009173 |
| 337 | REGULATION OF HEAT GENERATION | 2 | 15 | 0.0006813 | 0.009173 |
| 338 | REGULATION OF HAIR FOLLICLE DEVELOPMENT | 2 | 15 | 0.0006813 | 0.009173 |
| 339 | POSITIVE REGULATION OF CELLULAR COMPONENT ORGANIZATION | 10 | 1152 | 0.0006669 | 0.009173 |
| 340 | CELLULAR RESPONSE TO NITRIC OXIDE | 2 | 15 | 0.0006813 | 0.009173 |
| 341 | RESPONSE TO RADIATION | 6 | 413 | 0.0006821 | 0.009173 |
| 342 | RESPIRATORY BURST | 2 | 15 | 0.0006813 | 0.009173 |
| 343 | CHRONIC INFLAMMATORY RESPONSE | 2 | 15 | 0.0006813 | 0.009173 |
| 344 | POSITIVE REGULATION OF LIPID BIOSYNTHETIC PROCESS | 3 | 66 | 0.0006758 | 0.009173 |
| 345 | POSITIVE REGULATION OF MEMBRANE PROTEIN ECTODOMAIN PROTEOLYSIS | 2 | 15 | 0.0006813 | 0.009173 |
| 346 | T CELL APOPTOTIC PROCESS | 2 | 15 | 0.0006813 | 0.009173 |
| 347 | REGULATION OF PROTEIN LOCALIZATION | 9 | 950 | 0.0006912 | 0.009269 |
| 348 | NEGATIVE REGULATION OF CELLULAR CATABOLIC PROCESS | 4 | 156 | 0.0007206 | 0.009608 |
| 349 | CELLULAR RESPONSE TO INORGANIC SUBSTANCE | 4 | 156 | 0.0007206 | 0.009608 |
| 350 | NEGATIVE REGULATION OF NF KAPPAB TRANSCRIPTION FACTOR ACTIVITY | 3 | 68 | 0.0007374 | 0.009803 |
| Num | GO | Overlap | Size | P Value | Adj. P Value |
|---|---|---|---|---|---|
| 1 | KINASE ACTIVITY | 18 | 842 | 1.597e-12 | 1.484e-09 |
| 2 | CYTOKINE RECEPTOR BINDING | 12 | 271 | 3.83e-12 | 1.779e-09 |
| 3 | PHOSPHATIDYLINOSITOL 3 KINASE ACTIVITY | 8 | 70 | 9.923e-12 | 3.073e-09 |
| 4 | X1 PHOSPHATIDYLINOSITOL 3 KINASE ACTIVITY | 7 | 43 | 1.583e-11 | 3.676e-09 |
| 5 | TRANSFERASE ACTIVITY TRANSFERRING PHOSPHORUS CONTAINING GROUPS | 18 | 992 | 2.442e-11 | 4.537e-09 |
| 6 | TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY BINDING | 7 | 47 | 3.065e-11 | 4.746e-09 |
| 7 | PHOSPHATIDYLINOSITOL KINASE ACTIVITY | 7 | 51 | 5.598e-11 | 7.429e-09 |
| 8 | PROTEIN SERINE THREONINE KINASE ACTIVITY | 12 | 445 | 1.171e-09 | 1.36e-07 |
| 9 | PROTEIN KINASE ACTIVITY | 13 | 640 | 6.585e-09 | 6.797e-07 |
| 10 | TUMOR NECROSIS FACTOR RECEPTOR BINDING | 5 | 30 | 1.323e-08 | 1.229e-06 |
| 11 | ADENYL NUCLEOTIDE BINDING | 18 | 1514 | 2.139e-08 | 1.806e-06 |
| 12 | INTERLEUKIN 1 RECEPTOR BINDING | 4 | 16 | 7.224e-08 | 5.163e-06 |
| 13 | PHOSPHATIDYLINOSITOL PHOSPHATE KINASE ACTIVITY | 4 | 16 | 7.224e-08 | 5.163e-06 |
| 14 | ENZYME BINDING | 18 | 1737 | 1.748e-07 | 1.16e-05 |
| 15 | PROTEIN HETERODIMERIZATION ACTIVITY | 10 | 468 | 2.934e-07 | 1.817e-05 |
| 16 | UBIQUITIN LIKE PROTEIN LIGASE BINDING | 8 | 264 | 3.775e-07 | 2.192e-05 |
| 17 | DEATH RECEPTOR ACTIVITY | 4 | 24 | 4.154e-07 | 2.27e-05 |
| 18 | KINASE REGULATOR ACTIVITY | 7 | 186 | 5.049e-07 | 2.469e-05 |
| 19 | RIBONUCLEOTIDE BINDING | 18 | 1860 | 4.861e-07 | 2.469e-05 |
| 20 | INSULIN RECEPTOR SUBSTRATE BINDING | 3 | 11 | 2.695e-06 | 0.0001252 |
| 21 | CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY | 5 | 86 | 2.897e-06 | 0.0001282 |
| 22 | RECEPTOR BINDING | 15 | 1476 | 3.224e-06 | 0.0001362 |
| 23 | ENZYME REGULATOR ACTIVITY | 12 | 959 | 4.814e-06 | 0.0001945 |
| 24 | MOLECULAR FUNCTION REGULATOR | 14 | 1353 | 6.084e-06 | 0.0002355 |
| 25 | PROTEASE BINDING | 5 | 104 | 7.386e-06 | 0.0002541 |
| 26 | PROTEIN KINASE A CATALYTIC SUBUNIT BINDING | 3 | 15 | 7.378e-06 | 0.0002541 |
| 27 | CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY INVOLVED IN APOPTOTIC PROCESS | 3 | 15 | 7.378e-06 | 0.0002541 |
| 28 | DEATH RECEPTOR BINDING | 3 | 18 | 1.316e-05 | 0.0004366 |
| 29 | GROWTH FACTOR RECEPTOR BINDING | 5 | 129 | 2.105e-05 | 0.0006743 |
| 30 | SIGNAL TRANSDUCER ACTIVITY | 15 | 1731 | 2.22e-05 | 0.0006873 |
| 31 | KINASE BINDING | 9 | 606 | 2.331e-05 | 0.0006985 |
| 32 | CAMP BINDING | 3 | 23 | 2.83e-05 | 0.0008216 |
| 33 | PROTEIN DIMERIZATION ACTIVITY | 12 | 1149 | 2.961e-05 | 0.0008337 |
| 34 | IDENTICAL PROTEIN BINDING | 12 | 1209 | 4.874e-05 | 0.001332 |
| 35 | PROTEIN SERINE THREONINE KINASE INHIBITOR ACTIVITY | 3 | 30 | 6.405e-05 | 0.0017 |
| 36 | CYSTEINE TYPE PEPTIDASE ACTIVITY | 5 | 184 | 0.0001143 | 0.002869 |
| 37 | CYCLIC NUCLEOTIDE BINDING | 3 | 36 | 0.0001114 | 0.002869 |
| 38 | PROTEIN KINASE A BINDING | 3 | 42 | 0.0001772 | 0.00422 |
| 39 | CYSTEINE TYPE ENDOPEPTIDASE REGULATOR ACTIVITY INVOLVED IN APOPTOTIC PROCESS | 3 | 42 | 0.0001772 | 0.00422 |
| 40 | CYTOKINE ACTIVITY | 5 | 219 | 0.0002572 | 0.005972 |
| 41 | ENZYME INHIBITOR ACTIVITY | 6 | 378 | 0.0004282 | 0.009702 |
| Num | GO | Overlap | Size | P Value | Adj. P Value |
|---|---|---|---|---|---|
| 1 | TRANSFERASE COMPLEX TRANSFERRING PHOSPHORUS CONTAINING GROUPS | 13 | 237 | 2.755e-14 | 1.163e-11 |
| 2 | PHOSPHATIDYLINOSITOL 3 KINASE COMPLEX | 7 | 20 | 3.984e-14 | 1.163e-11 |
| 3 | MEMBRANE MICRODOMAIN | 13 | 288 | 3.358e-13 | 6.538e-11 |
| 4 | CATALYTIC COMPLEX | 17 | 1038 | 4.951e-10 | 7.229e-08 |
| 5 | TRANSFERASE COMPLEX | 14 | 703 | 1.984e-09 | 2.317e-07 |
| 6 | MEMBRANE PROTEIN COMPLEX | 16 | 1020 | 3.407e-09 | 3.316e-07 |
| 7 | PROTEIN KINASE COMPLEX | 6 | 90 | 1.209e-07 | 1.009e-05 |
| 8 | CILIARY BASE | 4 | 23 | 3.468e-07 | 2.532e-05 |
| 9 | EXTRINSIC COMPONENT OF MEMBRANE | 7 | 252 | 3.827e-06 | 0.0002483 |
| 10 | MEMBRANE REGION | 13 | 1134 | 4.675e-06 | 0.000273 |
| 11 | PLASMA MEMBRANE PROTEIN COMPLEX | 8 | 510 | 4.749e-05 | 0.002521 |
| 12 | VACUOLE | 11 | 1180 | 0.0001854 | 0.00886 |
| 13 | RECEPTOR COMPLEX | 6 | 327 | 0.0001972 | 0.00886 |
| 14 | INTRINSIC COMPONENT OF PLASMA MEMBRANE | 13 | 1649 | 0.0002327 | 0.009709 |
Over-represented Pathway
| Num | Pathway | Pathview | Overlap | Size | P Value | Adj. P Value |
|---|---|---|---|---|---|---|
| 1 | Apoptosis_hsa04210 | 33 | 138 | 5.298e-60 | 2.755e-58 | |
| 2 | TNF_signaling_pathway_hsa04668 | 19 | 108 | 1.025e-30 | 2.664e-29 | |
| 3 | NF_kappa_B_signaling_pathway_hsa04064 | 17 | 95 | 1.351e-27 | 2.342e-26 | |
| 4 | Necroptosis_hsa04217 | 18 | 164 | 3.623e-25 | 4.71e-24 | |
| 5 | MAPK_signaling_pathway_hsa04010 | 19 | 295 | 4.437e-22 | 4.615e-21 | |
| 6 | Sphingolipid_signaling_pathway_hsa04071 | 11 | 118 | 9.232e-15 | 8.001e-14 | |
| 7 | PI3K_Akt_signaling_pathway_hsa04151 | 14 | 352 | 2.045e-13 | 1.519e-12 | |
| 8 | Cellular_senescence_hsa04218 | 11 | 160 | 2.764e-13 | 1.796e-12 | |
| 9 | Ras_signaling_pathway_hsa04014 | 12 | 232 | 6.118e-13 | 3.535e-12 | |
| 10 | Autophagy_animal_hsa04140 | 10 | 128 | 1.017e-12 | 5.287e-12 | |
| 11 | FoxO_signaling_pathway_hsa04068 | 10 | 132 | 1.388e-12 | 6.562e-12 | |
| 12 | Apoptosis_multiple_species_hsa04215 | 7 | 33 | 2.14e-12 | 9.274e-12 | |
| 13 | Cytokine_cytokine_receptor_interaction_hsa04060 | 12 | 270 | 3.667e-12 | 1.467e-11 | |
| 14 | Focal_adhesion_hsa04510 | 10 | 199 | 8.341e-11 | 3.098e-10 | |
| 15 | VEGF_signaling_pathway_hsa04370 | 7 | 59 | 1.624e-10 | 5.629e-10 | |
| 16 | mTOR_signaling_pathway_hsa04150 | 9 | 151 | 1.749e-10 | 5.684e-10 | |
| 17 | Jak_STAT_signaling_pathway_hsa04630 | 9 | 162 | 3.278e-10 | 1.003e-09 | |
| 18 | Phospholipase_D_signaling_pathway_hsa04072 | 8 | 146 | 3.815e-09 | 1.102e-08 | |
| 19 | HIF_1_signaling_pathway_hsa04066 | 7 | 100 | 7.026e-09 | 1.923e-08 | |
| 20 | ErbB_signaling_pathway_hsa04012 | 6 | 85 | 8.577e-08 | 2.23e-07 | |
| 21 | AMPK_signaling_pathway_hsa04152 | 6 | 121 | 7.02e-07 | 1.738e-06 | |
| 22 | cAMP_signaling_pathway_hsa04024 | 7 | 198 | 7.692e-07 | 1.818e-06 | |
| 23 | Rap1_signaling_pathway_hsa04015 | 7 | 206 | 1.003e-06 | 2.268e-06 | |
| 24 | Signaling_pathways_regulating_pluripotency_of_stem_cells_hsa04550 | 6 | 139 | 1.583e-06 | 3.43e-06 | |
| 25 | Phosphatidylinositol_signaling_system_hsa04070 | 5 | 99 | 5.801e-06 | 1.207e-05 | |
| 26 | p53_signaling_pathway_hsa04115 | 4 | 68 | 2.926e-05 | 5.851e-05 | |
| 27 | Regulation_of_actin_cytoskeleton_hsa04810 | 5 | 208 | 0.0002026 | 0.0003901 | |
| 28 | Apelin_signaling_pathway_hsa04371 | 4 | 137 | 0.0004421 | 0.000821 | |
| 29 | cGMP_PKG_signaling_pathway_hsa04022 | 4 | 163 | 0.0008489 | 0.001522 | |
| 30 | Hedgehog_signaling_pathway_hsa04340 | 2 | 47 | 0.006651 | 0.01153 | |
| 31 | Oocyte_meiosis_hsa04114 | 2 | 124 | 0.04134 | 0.06935 | |
| 32 | Wnt_signaling_pathway_hsa04310 | 2 | 146 | 0.05536 | 0.08996 | |
| 33 | Calcium_signaling_pathway_hsa04020 | 2 | 182 | 0.08127 | 0.1281 |
lncRNA-mediated sponge
| Num | lncRNA | miRNAs | miRNAs count | Gene | Sponge regulatory network | lncRNA log2FC | lncRNA pvalue | Gene log2FC | Gene pvalue | lncRNA-gene Pearson correlation |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | MAGI2-AS3 |
hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-142-3p;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-3065-5p;hsa-miR-362-3p;hsa-miR-93-5p | 10 | AKT3 | Sponge network | 0.331 | 0.60413 | 0.2 | 0.64987 | 0.454 |
| 2 | RP11-389C8.2 |
hsa-let-7a-3p;hsa-let-7f-1-3p;hsa-miR-141-3p;hsa-miR-16-2-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-183-5p;hsa-miR-18a-5p;hsa-miR-193a-3p;hsa-miR-19a-3p;hsa-miR-19b-3p;hsa-miR-200a-3p;hsa-miR-200c-3p;hsa-miR-2110;hsa-miR-3065-5p;hsa-miR-429;hsa-miR-93-5p | 17 | PRKACB | Sponge network | 0.195 | 0.62434 | -0.038 | 0.95004 | 0.394 |
| 3 | RP11-284N8.3 | hsa-miR-141-3p;hsa-miR-16-2-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-183-5p;hsa-miR-18a-5p;hsa-miR-19b-3p;hsa-miR-200a-3p;hsa-miR-3065-5p;hsa-miR-590-5p;hsa-miR-93-5p;hsa-miR-96-5p | 12 | PRKACB | Sponge network | -0.377 | 0.61261 | -0.038 | 0.95004 | 0.371 |
| 4 | RP11-389C8.2 |
hsa-miR-15b-3p;hsa-miR-15b-5p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-200a-5p;hsa-miR-200b-3p;hsa-miR-200b-5p;hsa-miR-200c-3p;hsa-miR-20a-3p;hsa-miR-24-2-5p;hsa-miR-3065-5p;hsa-miR-429;hsa-miR-629-5p | 13 | BCL2 | Sponge network | 0.195 | 0.62434 | -0.089 | 0.85335 | 0.366 |
| 5 | MAGI2-AS3 |
hsa-let-7a-3p;hsa-let-7f-1-3p;hsa-miR-141-3p;hsa-miR-16-2-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-183-5p;hsa-miR-18a-5p;hsa-miR-193a-3p;hsa-miR-19a-3p;hsa-miR-19b-3p;hsa-miR-200a-3p;hsa-miR-200c-3p;hsa-miR-2110;hsa-miR-3065-5p;hsa-miR-30d-3p;hsa-miR-362-3p;hsa-miR-429;hsa-miR-590-3p;hsa-miR-93-5p | 20 | PRKACB | Sponge network | 0.331 | 0.60413 | -0.038 | 0.95004 | 0.359 |
| 6 | AC003090.1 |
hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-22-5p;hsa-miR-320b;hsa-miR-320c;hsa-miR-330-3p;hsa-miR-582-5p;hsa-miR-590-3p;hsa-miR-590-5p;hsa-miR-629-3p | 15 | PIK3R1 | Sponge network | 0.466 | 0.8099 | -0.149 | 0.83268 | 0.358 |
| 7 | DNM3OS |
hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-142-3p;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-3065-5p;hsa-miR-502-3p;hsa-miR-93-5p | 10 | AKT3 | Sponge network | -0.264 | 0.65518 | 0.2 | 0.64987 | 0.354 |
| 8 | RP11-774O3.3 |
hsa-miR-15b-3p;hsa-miR-15b-5p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-200b-5p;hsa-miR-200c-3p;hsa-miR-20a-3p;hsa-miR-21-5p;hsa-miR-24-2-5p;hsa-miR-32-3p;hsa-miR-33b-5p;hsa-miR-365a-3p;hsa-miR-7-5p | 13 | BCL2 | Sponge network | 0.004 | 0.98793 | -0.089 | 0.85335 | 0.35 |
| 9 | HAND2-AS1 |
hsa-miR-15b-3p;hsa-miR-15b-5p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-200a-5p;hsa-miR-200b-3p;hsa-miR-200b-5p;hsa-miR-200c-3p;hsa-miR-20a-3p;hsa-miR-21-5p;hsa-miR-24-2-5p;hsa-miR-32-3p;hsa-miR-33b-5p;hsa-miR-365a-3p;hsa-miR-429;hsa-miR-582-5p;hsa-miR-629-5p;hsa-miR-7-5p | 18 | BCL2 | Sponge network | 0.477 | 0.68532 | -0.089 | 0.85335 | 0.35 |
| 10 | ADAMTS9-AS1 |
hsa-miR-15b-3p;hsa-miR-15b-5p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-200a-5p;hsa-miR-200b-3p;hsa-miR-200b-5p;hsa-miR-200c-3p;hsa-miR-20a-3p;hsa-miR-21-5p;hsa-miR-215-5p;hsa-miR-24-2-5p;hsa-miR-365a-3p;hsa-miR-429;hsa-miR-582-5p;hsa-miR-590-5p;hsa-miR-629-5p;hsa-miR-7-5p | 18 | BCL2 | Sponge network | 0.804 | 0.67055 | -0.089 | 0.85335 | 0.346 |
| 11 | DNM3OS |
hsa-let-7f-1-3p;hsa-miR-141-3p;hsa-miR-16-2-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-183-5p;hsa-miR-18a-5p;hsa-miR-193a-3p;hsa-miR-19a-3p;hsa-miR-19b-3p;hsa-miR-200a-3p;hsa-miR-200c-3p;hsa-miR-2110;hsa-miR-3065-5p;hsa-miR-30d-3p;hsa-miR-429;hsa-miR-590-3p;hsa-miR-590-5p;hsa-miR-93-5p;hsa-miR-96-5p | 20 | PRKACB | Sponge network | -0.264 | 0.65518 | -0.038 | 0.95004 | 0.336 |
| 12 | AC003090.1 |
hsa-miR-15b-3p;hsa-miR-15b-5p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-200a-5p;hsa-miR-200b-5p;hsa-miR-200c-3p;hsa-miR-20a-3p;hsa-miR-21-5p;hsa-miR-24-2-5p;hsa-miR-33b-5p;hsa-miR-365a-3p;hsa-miR-582-5p;hsa-miR-590-5p | 14 | BCL2 | Sponge network | 0.466 | 0.8099 | -0.089 | 0.85335 | 0.326 |
| 13 | HOXA11-AS |
hsa-miR-141-3p;hsa-miR-16-2-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-183-5p;hsa-miR-18a-5p;hsa-miR-193a-3p;hsa-miR-19a-3p;hsa-miR-19b-3p;hsa-miR-200a-3p;hsa-miR-200c-3p;hsa-miR-2110 | 12 | PRKACB | Sponge network | 0.402 | 0.37439 | -0.038 | 0.95004 | 0.326 |
| 14 | MIR497HG |
hsa-miR-15b-3p;hsa-miR-15b-5p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-200a-5p;hsa-miR-200b-3p;hsa-miR-200b-5p;hsa-miR-200c-3p;hsa-miR-20a-3p;hsa-miR-21-5p;hsa-miR-24-2-5p;hsa-miR-590-5p;hsa-miR-7-5p | 13 | BCL2 | Sponge network | -0.497 | 0.59613 | -0.089 | 0.85335 | 0.322 |
| 15 | RAMP2-AS1 | hsa-miR-192-5p;hsa-miR-200b-5p;hsa-miR-200c-3p;hsa-miR-21-5p;hsa-miR-215-5p;hsa-miR-24-2-5p;hsa-miR-32-3p;hsa-miR-338-5p;hsa-miR-33b-5p;hsa-miR-365a-3p;hsa-miR-629-5p | 11 | BCL2 | Sponge network | -0.018 | 0.98142 | -0.089 | 0.85335 | 0.313 |
| 16 | MIR497HG |
hsa-miR-1301-3p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-22-5p;hsa-miR-320c;hsa-miR-584-5p;hsa-miR-590-5p;hsa-miR-629-3p | 13 | PIK3R1 | Sponge network | -0.497 | 0.59613 | -0.149 | 0.83268 | 0.307 |
| 17 | RP11-119F7.5 | hsa-miR-15b-3p;hsa-miR-16-2-3p;hsa-miR-192-5p;hsa-miR-200a-5p;hsa-miR-200b-3p;hsa-miR-200b-5p;hsa-miR-21-5p;hsa-miR-215-5p;hsa-miR-24-2-5p;hsa-miR-33b-5p | 10 | BCL2 | Sponge network | 0.519 | 0.48018 | -0.089 | 0.85335 | 0.307 |
| 18 | MIR143HG |
hsa-miR-15b-3p;hsa-miR-15b-5p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-192-5p;hsa-miR-200a-5p;hsa-miR-200b-3p;hsa-miR-200b-5p;hsa-miR-200c-3p;hsa-miR-20a-3p;hsa-miR-21-5p;hsa-miR-215-5p;hsa-miR-24-2-5p;hsa-miR-3065-5p;hsa-miR-33b-5p;hsa-miR-429;hsa-miR-590-5p;hsa-miR-629-5p;hsa-miR-7-5p | 19 | BCL2 | Sponge network | 0.188 | 0.86553 | -0.089 | 0.85335 | 0.304 |
| 19 | NR2F1-AS1 |
hsa-miR-15b-3p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-200c-3p;hsa-miR-20a-3p;hsa-miR-21-5p;hsa-miR-24-2-5p;hsa-miR-33b-5p;hsa-miR-365a-3p;hsa-miR-629-5p;hsa-miR-7-5p | 11 | BCL2 | Sponge network | -0.165 | 0.76959 | -0.089 | 0.85335 | 0.303 |
| 20 | RP11-774O3.3 |
hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-22-5p;hsa-miR-32-3p;hsa-miR-320b;hsa-miR-320c;hsa-miR-330-3p;hsa-miR-335-3p;hsa-miR-590-3p;hsa-miR-629-3p | 14 | PIK3R1 | Sponge network | 0.004 | 0.98793 | -0.149 | 0.83268 | 0.303 |
| 21 | LINC00865 |
hsa-miR-141-3p;hsa-miR-16-2-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-183-5p;hsa-miR-18a-5p;hsa-miR-19a-3p;hsa-miR-19b-3p;hsa-miR-200a-3p;hsa-miR-200c-3p;hsa-miR-2110;hsa-miR-30d-3p;hsa-miR-429 | 13 | PRKACB | Sponge network | 0.259 | 0.70261 | -0.038 | 0.95004 | 0.302 |
| 22 | CTC-296K1.3 | hsa-let-7f-1-3p;hsa-miR-141-3p;hsa-miR-16-2-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-18a-5p;hsa-miR-193a-3p;hsa-miR-19a-3p;hsa-miR-19b-3p;hsa-miR-200a-3p;hsa-miR-2110 | 11 | PRKACB | Sponge network | -0.171 | 0.8851 | -0.038 | 0.95004 | 0.302 |
| 23 | RP11-532F6.3 | hsa-miR-15b-3p;hsa-miR-15b-5p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-200a-5p;hsa-miR-200b-3p;hsa-miR-200b-5p;hsa-miR-200c-3p;hsa-miR-20a-3p;hsa-miR-24-2-5p;hsa-miR-33b-5p | 11 | BCL2 | Sponge network | -0.11 | 0.87335 | -0.089 | 0.85335 | 0.299 |
| 24 | ACTA2-AS1 |
hsa-miR-15b-3p;hsa-miR-15b-5p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-200a-5p;hsa-miR-200b-3p;hsa-miR-200b-5p;hsa-miR-200c-3p;hsa-miR-20a-3p;hsa-miR-21-5p;hsa-miR-215-5p;hsa-miR-24-2-5p;hsa-miR-33b-5p;hsa-miR-7-5p | 14 | BCL2 | Sponge network | -0.694 | 0.57395 | -0.089 | 0.85335 | 0.298 |
| 25 | RP11-389C8.2 |
hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-22-5p;hsa-miR-3065-5p;hsa-miR-330-3p;hsa-miR-335-3p;hsa-miR-629-3p | 11 | PIK3R1 | Sponge network | 0.195 | 0.62434 | -0.149 | 0.83268 | 0.297 |
| 26 | MAGI2-AS3 |
hsa-miR-141-3p;hsa-miR-148b-5p;hsa-miR-188-5p;hsa-miR-20a-3p;hsa-miR-324-5p;hsa-miR-421;hsa-miR-429;hsa-miR-501-5p;hsa-miR-590-3p;hsa-miR-660-5p;hsa-miR-9-3p;hsa-miR-92a-3p | 12 | IRAK3 | Sponge network | 0.331 | 0.60413 | 0.548 | 0.25565 | 0.295 |
| 27 | TRHDE-AS1 |
hsa-miR-15b-3p;hsa-miR-15b-5p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-200a-5p;hsa-miR-200b-3p;hsa-miR-200b-5p;hsa-miR-200c-3p;hsa-miR-20a-3p;hsa-miR-21-5p;hsa-miR-24-2-5p;hsa-miR-32-3p;hsa-miR-33b-5p;hsa-miR-429;hsa-miR-582-5p;hsa-miR-590-5p;hsa-miR-7-5p | 17 | BCL2 | Sponge network | -0.585 | 0.75149 | -0.089 | 0.85335 | 0.295 |
| 28 | FAM66C |
hsa-let-7a-3p;hsa-let-7f-1-3p;hsa-miR-16-2-3p;hsa-miR-17-5p;hsa-miR-18a-5p;hsa-miR-193a-3p;hsa-miR-19a-3p;hsa-miR-19b-3p;hsa-miR-2110;hsa-miR-429;hsa-miR-590-3p;hsa-miR-590-5p | 12 | PRKACB | Sponge network | 0.289 | 0.68737 | -0.038 | 0.95004 | 0.294 |
| 29 | FAM225B | hsa-miR-141-3p;hsa-miR-16-2-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-183-5p;hsa-miR-18a-5p;hsa-miR-200a-3p;hsa-miR-200c-3p;hsa-miR-3065-5p;hsa-miR-590-3p;hsa-miR-93-5p | 11 | PRKACB | Sponge network | 0.445 | 0.47288 | -0.038 | 0.95004 | 0.293 |
| 30 | NR2F1-AS1 |
hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-22-5p;hsa-miR-29b-3p;hsa-miR-320b;hsa-miR-330-3p;hsa-miR-590-3p;hsa-miR-629-3p | 12 | PIK3R1 | Sponge network | -0.165 | 0.76959 | -0.149 | 0.83268 | 0.292 |
| 31 | RP11-567M16.1 |
hsa-miR-1301-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-29b-3p;hsa-miR-320b;hsa-miR-330-3p;hsa-miR-335-3p;hsa-miR-590-5p;hsa-miR-629-3p | 11 | PIK3R1 | Sponge network | 0.111 | 0.93576 | -0.149 | 0.83268 | 0.286 |
| 32 | DNM3OS |
hsa-miR-1301-3p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-3065-5p;hsa-miR-32-3p;hsa-miR-320b;hsa-miR-320c;hsa-miR-330-3p;hsa-miR-590-3p;hsa-miR-590-5p;hsa-miR-629-3p | 15 | PIK3R1 | Sponge network | -0.264 | 0.65518 | -0.149 | 0.83268 | 0.285 |
| 33 | FAM66C |
hsa-miR-15b-3p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-200a-5p;hsa-miR-200b-3p;hsa-miR-200b-5p;hsa-miR-20a-3p;hsa-miR-21-5p;hsa-miR-24-2-5p;hsa-miR-33b-5p;hsa-miR-429;hsa-miR-590-5p;hsa-miR-7-5p | 13 | BCL2 | Sponge network | 0.289 | 0.68737 | -0.089 | 0.85335 | 0.284 |
| 34 | LINC00284 |
hsa-miR-18a-3p;hsa-miR-19b-3p;hsa-miR-222-5p;hsa-miR-29b-1-5p;hsa-miR-330-3p;hsa-miR-330-5p;hsa-miR-365a-3p;hsa-miR-511-5p;hsa-miR-590-3p;hsa-miR-590-5p | 10 | PIK3R3 | Sponge network | 0.193 | 0.90734 | 0.01 | 0.98958 | 0.283 |
| 35 | RP11-166D19.1 |
hsa-let-7a-3p;hsa-let-7f-1-3p;hsa-miR-141-3p;hsa-miR-16-2-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-183-5p;hsa-miR-18a-5p;hsa-miR-193a-3p;hsa-miR-19a-3p;hsa-miR-19b-3p;hsa-miR-200a-3p;hsa-miR-200c-3p;hsa-miR-30d-3p;hsa-miR-429;hsa-miR-590-3p;hsa-miR-590-5p;hsa-miR-96-5p | 18 | PRKACB | Sponge network | 0.333 | 0.48662 | -0.038 | 0.95004 | 0.282 |
| 36 | RP11-774O3.3 |
hsa-let-7a-3p;hsa-let-7f-1-3p;hsa-miR-16-2-3p;hsa-miR-17-5p;hsa-miR-183-5p;hsa-miR-18a-5p;hsa-miR-193a-3p;hsa-miR-200c-3p;hsa-miR-2110;hsa-miR-590-3p | 10 | PRKACB | Sponge network | 0.004 | 0.98793 | -0.038 | 0.95004 | 0.28 |
| 37 | AC003090.1 |
hsa-let-7f-1-3p;hsa-miR-141-3p;hsa-miR-16-2-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-183-5p;hsa-miR-18a-5p;hsa-miR-193a-3p;hsa-miR-19a-3p;hsa-miR-19b-3p;hsa-miR-200c-3p;hsa-miR-2110;hsa-miR-590-3p;hsa-miR-590-5p;hsa-miR-93-5p;hsa-miR-96-5p | 16 | PRKACB | Sponge network | 0.466 | 0.8099 | -0.038 | 0.95004 | 0.279 |
| 38 | NR2F1-AS1 |
hsa-miR-18a-3p;hsa-miR-19b-3p;hsa-miR-222-5p;hsa-miR-29b-1-5p;hsa-miR-32-5p;hsa-miR-330-3p;hsa-miR-330-5p;hsa-miR-365a-3p;hsa-miR-511-5p;hsa-miR-590-3p;hsa-miR-92a-3p | 11 | PIK3R3 | Sponge network | -0.165 | 0.76959 | 0.01 | 0.98958 | 0.279 |
| 39 | MAGI2-AS3 |
hsa-miR-15b-3p;hsa-miR-15b-5p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-200a-5p;hsa-miR-200b-3p;hsa-miR-200b-5p;hsa-miR-200c-3p;hsa-miR-20a-3p;hsa-miR-21-5p;hsa-miR-24-2-5p;hsa-miR-3065-5p;hsa-miR-32-3p;hsa-miR-33b-5p;hsa-miR-365a-3p;hsa-miR-429;hsa-miR-629-5p;hsa-miR-7-5p | 18 | BCL2 | Sponge network | 0.331 | 0.60413 | -0.089 | 0.85335 | 0.277 |
| 40 | ZNF667-AS1 |
hsa-miR-15b-3p;hsa-miR-15b-5p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-200c-3p;hsa-miR-20a-3p;hsa-miR-21-5p;hsa-miR-24-2-5p;hsa-miR-590-5p;hsa-miR-629-5p;hsa-miR-7-5p | 11 | BCL2 | Sponge network | 0.158 | 0.77515 | -0.089 | 0.85335 | 0.273 |
| 41 | ZNF667-AS1 |
hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-22-5p;hsa-miR-29b-3p;hsa-miR-320c;hsa-miR-590-5p;hsa-miR-629-3p | 11 | PIK3R1 | Sponge network | 0.158 | 0.77515 | -0.149 | 0.83268 | 0.273 |
| 42 | HAND2-AS1 |
hsa-let-7a-3p;hsa-let-7f-1-3p;hsa-miR-141-3p;hsa-miR-16-2-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-183-5p;hsa-miR-18a-5p;hsa-miR-193a-3p;hsa-miR-19a-3p;hsa-miR-19b-3p;hsa-miR-200a-3p;hsa-miR-200c-3p;hsa-miR-2110;hsa-miR-429;hsa-miR-590-3p;hsa-miR-93-5p | 17 | PRKACB | Sponge network | 0.477 | 0.68532 | -0.038 | 0.95004 | 0.272 |
| 43 | PWAR6 | hsa-miR-15b-3p;hsa-miR-15b-5p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-200b-5p;hsa-miR-20a-3p;hsa-miR-21-5p;hsa-miR-24-2-5p;hsa-miR-33b-5p;hsa-miR-629-5p | 10 | BCL2 | Sponge network | -0.138 | 0.85495 | -0.089 | 0.85335 | 0.271 |
| 44 | ACTA2-AS1 |
hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-22-5p;hsa-miR-29b-3p;hsa-miR-590-3p | 10 | PIK3R1 | Sponge network | -0.694 | 0.57395 | -0.149 | 0.83268 | 0.264 |
| 45 | C1RL-AS1 |
hsa-miR-148b-5p;hsa-miR-188-5p;hsa-miR-20a-3p;hsa-miR-3200-3p;hsa-miR-361-5p;hsa-miR-421;hsa-miR-501-5p;hsa-miR-590-3p;hsa-miR-590-5p;hsa-miR-660-5p | 10 | IRAK3 | Sponge network | -0.04 | 0.90521 | 0.548 | 0.25565 | 0.261 |
| 46 | RP11-999E24.3 | hsa-miR-15b-3p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-20a-3p;hsa-miR-21-5p;hsa-miR-215-5p;hsa-miR-24-2-5p;hsa-miR-33b-5p;hsa-miR-7-5p | 11 | BCL2 | Sponge network | 0.441 | 0.52389 | -0.089 | 0.85335 | 0.258 |
| 47 | TPTEP1 |
hsa-miR-15b-3p;hsa-miR-15b-5p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-200a-5p;hsa-miR-200b-5p;hsa-miR-200c-3p;hsa-miR-20a-3p;hsa-miR-24-2-5p;hsa-miR-33b-5p;hsa-miR-365a-3p;hsa-miR-7-5p | 12 | BCL2 | Sponge network | 0.213 | 0.82899 | -0.089 | 0.85335 | 0.257 |
| 48 | MIR143HG |
hsa-let-7f-1-3p;hsa-miR-141-3p;hsa-miR-16-2-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-183-5p;hsa-miR-18a-5p;hsa-miR-193a-3p;hsa-miR-19a-3p;hsa-miR-19b-3p;hsa-miR-200a-3p;hsa-miR-200c-3p;hsa-miR-2110;hsa-miR-3065-5p;hsa-miR-30d-3p;hsa-miR-429;hsa-miR-590-3p;hsa-miR-590-5p;hsa-miR-93-5p | 19 | PRKACB | Sponge network | 0.188 | 0.86553 | -0.038 | 0.95004 | 0.253 |
| 49 | RP11-400K9.4 | hsa-miR-141-3p;hsa-miR-16-2-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-183-5p;hsa-miR-18a-5p;hsa-miR-19a-3p;hsa-miR-19b-3p;hsa-miR-200a-3p;hsa-miR-93-5p | 10 | PRKACB | Sponge network | 0.205 | 0.70757 | -0.038 | 0.95004 | 0.253 |
| 50 | WT1-AS |
hsa-miR-15b-3p;hsa-miR-15b-5p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-200a-5p;hsa-miR-200b-3p;hsa-miR-200b-5p;hsa-miR-200c-3p;hsa-miR-20a-3p;hsa-miR-24-2-5p;hsa-miR-32-3p;hsa-miR-429;hsa-miR-629-5p | 13 | BCL2 | Sponge network | 0.547 | 0.65455 | -0.089 | 0.85335 | 0.253 |